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ABBREVIATIONS
The abbreviations used in this thesis are those recommended in the 
Instructions To Authors of the Biochemical Journal (1986), with the following
additions :-
A 492 Absorbance readings at 492nm.
ADCC Antibody-dependent cellular cytotoxicity
BSA Bovine serum albumin
CFA Complement fixation assay
CHO Carbohydrate
CON Control
Con A Concanavalin A
CSP Castanospermine
DARIg Donkey anti-rabbit immunoglobulin
dGlc 2-deoxyglucose
dMM 1 -deoxymannojirimycin
DMSO Dimethyl sulphoxide
dNM 1-deoxynojirimycin
Dol Dolichol
3D-TKM Three-detergent cocktail in TKM buffer
Elisa Enzyme linked immuno sorbent assay
Endo H Endo-a-N-acetylglucosaminidase H
FCS Foetal calf serum
y Heavy chains of IgG
HA Haemagglutinin
HRP Horse radish peroxidase
HR(S) Hours(s)
Ig Immunoglobulin
L Light chains
LPS Lipopolysaccharide
Heavy chains of IgM
mem Membrane-form immunoglobulins
MHC Major Histocompatibility Complex
Mr Relative molecular mass
NANase Neuraminidase
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate-buffered saline
RArlg Rabbit antibody to rat immunoglobulin heavy And light chains
sec Secretory immunoglobulins
SW Swainsonine
TCA Trichloroacetic acid
TEMED N,N,N',N'-Tetramethylethylene diamine
TKM Tris-potassium-magnesium buffer
TM Tunicamydn (-treated)
TM-1, -2 o r-3 Analogues of tunicamycin (-treated)
VSV Vesicular Stomatitis Virus
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SUMMARY
The functions of carbohydrate moieties of glycoproteins are subject to 
much controversy. Their role in the regulation of intracellular glycoprotein transport 
is obscured by the discovery of distinctive effects that result from treatment either 
with inhibitors of N-glycosylation or intracellular N-linked oligosaccharide 
processing. It is therefore the purpose of this study to ratify and to broaden the 
perspective in this area of ambiguity.
The experimental approach used in the investigation generally involves 
biosynthetic labelling of rat hybridoma cells with various radioactive precursor and 
an isolation of intracellular and/or extracellular immunoglobulins by 
immunoprecipitation technique. Through properly-timed, pulse-chase methods, it 
was possible to determine the effects of various inhibitors of glycosylation or 
oligosaccharide processing on the kinetics of immunoglobulin export. The isolated 
immunoglobulins were also subjected to other analyses to identify and to confirm 
the structures of carbohydrate molecules that were im&porated, as well as to assess 
the effects of inhibition of N-glycosylation or N-linked oligosaccharide processing 
on the biological functions of immunoglobulins.
The first part of this study involves characterization of three structural 
analogues of tunicamycin, TM-1, TM-2 and TM-3. Results from this investigation 
demonstrate that minor modifications to the structure of the antibiotic results in the 
loss of its biological activity (i.e., with respect to inhibition of N-glycosylation). 
The analogues do not inhibit N-glycosylation of immunoglobulins and have no 
effects on the kinetics of IgM and IgG2b secretion from rat hybridomas. The data, 
therefore,Su6jfast that the selective inhibition of immunoglobulin secretion that is 
observed when cells are treated with tunicamycin is really due to the absence of
XV
carbohydrate moieties from the immune molecules and not a direct effect of the 
antibiotic.
The data also demonstrate, that unlike normal tunicamycin, the three 
structural analogues are not cytotoxic. Their presence has no pronounced effect on 
the cellular uptake of tritiated-thymidine, -uridine and -leucine. This suggests that 
the well-recognized cytotoxic effects of tunicamycin are also a secondary effect due 
to the action of the drug on other cellular functions. In addition, enzymatic analysis 
of isolated immunoglobulins produced and secreted in the presence of the three 
tunicamycin analogues demonstrates that the drugs have no effect on the N- 
acetylglucosaminyl transferase I and II activities located in the Golgi apparatus. 
Susceptibility to endo H digestion is only observed in immunoglobulins isolated 
from within the cells. Immunoglobulins secreted in the presence of the analogues of 
tunicamycin display complete resistance to the enzyme.
To provide a wider perspective on the current understanding of the role of 
N-linked carbohydrate processing in the regulation of glycoprotein transport, a 
study of the effects of four specific N-linked oligosaccharide processing inhibitors 
(i.e., CSP, dNM, dMM and SW) on the secretion of IgM and IgG2 b from rat 
hybridoma lines was carried out. The data clearly demonstrate that inhibition of the 
processing of N-linked oligosaccharide at specific stages of the pathway does not 
lead to any significant interference with the rate of IgM and IgG2b secretion.
Resolution of the reduced immunoglobulin components secreted from 
cells that were treated with the individual processing inhibitors on SDS-PAGE 
demonstrate distinctive heavy chain structures. While no apparent difference could 
be seen from the p- and y-heavy chains that were secreted in the presence of the 
mannosidase Ia/b and II inhibitors (i.e., dMM and SW, respectively), treatment
with glucosidase inhibitors (i.e., CSP and dNM) results in the production of p- and 
y-heavy chains with higher Mr.
Experiments were also performed by using mixtures of the carbohydrate 
processing inhibitors. Treatment of IIA 1.4 and 4A3 cells with selective pairs of 
glucosidase and mannosidase inhibitors (i.e., CSP/SW and dNM/dMM) or with all 
the four processing inhibitors simultaneously, also demonstrate no significant 
changes of the rate of immunoglobulin export. The p- and y-heavy chains that were 
isolated in all of these cases, however, demonstrate the higher-type Mr structures.
The oligosaccharide chains of IgG2b fr°m I1A1.4 cells, under normal 
circumstances, although bearing the complex-type structures, do not possess 
terminally-linked sialic acid residues. By using neuraminidase digestion analysis, it 
was shown that when the processing of the carbohydrate moieties was inhibited by 
any of the four processing inhibitors, individually, or with all of them 
simultaneously, y-heavy chains become susceptible to the enzyme treatment, 
suggesting the presence of terminally-linked sialic acid residues. This effect may 
either be a result of a direct activation of intracellular sialyl transferase or due to 
other processing resulting in carbohydrate configurations which can act as 
substrates for the transferase.
N-linked carbohydrate moieties of immunoglobulins have been strongly 
implicated to be involved in the Clq-binding interaction. Their absence from 
immunoglobulins have rendered the molecules less effective in activating the 
complement cascade. The data from experiments performed in this study are also 
compatible with this interpretation. A similar result was obtained when 
tunicamycin-treated non-N-glycosylated IgG2b from IIA 1.4 cells was subjected to 
complement fixation assay.
In the case of immunoglobulins with high mannose structures that were 
secreted in the presence of oligosaccharide processing inhibitors, the data indicate 
otherwise. These immunoglobulins apparently possess potentiated capability in 
fixing complement. Complement fixation assays were also performed on normal 
IgG2b i*1 presence of free mannose, galactose and N-acetylglucosamine at 5mM 
concentration. The monosaccharides have no effect on the complement fixation 
activity.
The effects of inhibition of N-glycosylation or oligosaccharide processing 
on Fc-binding interactions, which may involve carbohydrate moieties, have also 
been studied. The data indicate that neither the inhibition of N-glycosylation nor 
carbohydrate processing have any consequence on antibody-dependent 
haemagglutination by IgG2b from I1A1.4 cells. In addition, inhibition of N- 
glycosylation or the processing of carbohydrate moieties of IgG2b was a*so shown 
to have no effect on antigen binding capacity of the immunoglobulins.
CHAPTER I  
INTRODUCTION
1.1. Glycoproteins.
Glycoproteins are proteins containing carbohydrate chains covalently 
attached to selected amino acid residues. The carbohydrate chains of glycoproteins 
range from simple disaccharide molecules to very complex, highly branched 
structures. The term glycoprotein, however, excludes proteins with extensive 
polysaccharide linkages. These carbohydrate-linked proteins are specially classified 
as proteoglycans. Glycoproteins, proteoglycans and glycolipids fall within a single 
class of macromolecule known as the glycoconjugates (Hughes, 1983).
Carbohydrate moieties of glycoproteins are linked either O-glycosidically, 
from N-acetylgalactosamine to the hydroxyl groups of serine or threonine residues 
of the peptide, or N-glycosidically, via the amino group of N-acetylglucosamine to 
the amide nitrogen of a peptidyl asparagine. O-linked oligosaccharide linkages have 
also been reported to exist between other sugars and amino acids, e.g., mannose, 
hydoxyproline and hydroxylysine (Hughes, 1983). This thesis focuses only on N- 
linked oligosaccharide moieties of glycoproteins, with particular reference to those 
associated with immunoglobulin molecules.
1.2. N-Linked Oligosaccharides of Glycoproteins.
1.2.1. Assembly and Transfer of Lipid-Linked Oligosaccharide.
Prior to glycosylation, N-linked oligosaccharide moieties are initially built 
on an activated lipid carrier, dolichol phosphate. Dolichol is a family of 
polyisoprenols which are found in the tissues of a variety of eukaiyotes (Struck and 
Lennarz, 1980). Figure 1 demonstrates the biosynthetic pathway of the lipid-linked 
oligosaccharide complex. Upon phosphorylation, dolichol sequentially acquires the 
various monosaccharides starting with the transfer of a single N-acetylglucosamine 
residue (Parodi and Leloir, 1979). This step can be specifically inhibited by 
tunicamycin, a drug that abrogates N-glycosylation of glycoproteins (see section
Figure 1. Assembly of lipid-linked oligosaccharides.
Prior to their transfer to nascent proteins, oligosaccharides are initially built on 
dolichol phosphate. Sugars are added sequentially with the first seven 
monosaccharides derived from nucleotide-sugar complexes whereas the next seven 
monosaccharides are derived from lipid intermediates (for references, see section 
2 . 1).
KEY;
Dol-P - dolichol phosphate
GlcNAc - N-acetylglucosamine
Man - mannose
Glc - glucose
Dol-P
UDP-GlcNAc
UMP
DoI-P-P-GIcNAc
UDP-GlcNAc-----
UDP
Dol-P-P-(GlcNAc)
5GDP-Man-----
4Dol-P-Man
5GDP
4Dol-P
Dol-P-P-(GlcNAc), (Man)
3Dol-P-Glc
3Dol-P
Dol-P-P-(GlcNAc) JM an)ft (GIc) 
Protein-Asn
Dol-P-P
Protein-Asn-(GlcNAc)2 (Man) (GIc)
2
1.3.1.2). Addition of another N-acetylglucosamine, 9 mannose and 3 glucose 
units, follow sequentially (Li et al.y 1978; Hubbard and Robbins, 1979). While the 
internal sugars are transferred from nucleotide-linked precursors, peripheral 
monosaccharides are derived from lipid-linked intermediates (Elbein, 1979; Parodi 
and Leloir, 1979). The complete precursor-type oligosaccharide structure is then 
transferred to the proteins.
The acceptor-site on the nascent polypeptide has been demonstrated to 
comprise a specific tripeptide sequence consisting of asparagine-X-threonine/serine, 
where X may be any amino acid with the exceptions of aspartic acid and proline 
(Marshall, 1972 and 1974). The requirement for the specific sequence has been 
assessed by Bause and Legler (1981) by experimenting on a series of 
oligopeptides. They have come to the conclusion that a nearby hydroxylated amino 
acid is required for the formation of a hydrogen bond with the amide of asparagine 
to achieve a higher reactivity toward the glycosyl donor. Studies have also shown 
that not all tripeptide sequences of this nature are glycosylated (Kronquist and 
Lennarz, 1978). Glycosylation is apparently dependent on the tertiary conformation 
of the protein, and has been demonstrated to be favoured by a p-tum or loop 
structures (Aubert etal., 1976; Beeley, 1977; Bause, 1983).
1.2.2. N-Linked Oligosaccharide Processing and Modification.
The N-linked oligosaccharide processing pathway and the subcellular 
locations of the various reactions involved is schematically represented in figure 2. 
Once transferred to the nascent polypeptide, N-linked oligosaccharides undergo 
extensive processing, initiated by removal of the terminal glucose residues by the 
action of a(l,2)-specific glucosidase I (Hettkamp et al.y 1984). This creates the 
substrate for glucosidase II which subsequently cleaves the remaining a(l,3)-linked 
glucose units (Bums and Touster, 1982; Brada and Dubach, 1984). Also within the
3
Figure 2. Processing of N-linked oligosaccharides of glycoproteins.
The N-linked oligosaccharide processing pathway and the subcellular locations of 
the various reactions involved is schematically illustrated (for references, see 
section 2.2). In the rough endoplasmic reticulum (RER) all of the glucose and one 
of the mannose residues are firstly being trimmed. Upon entry into the cis 
compartment of the Golgi apparatus, oligosaccharides of lysosomal glycoproteins 
undergo phosphorylation reaction. Secretory and membrane-associated 
glycoproteins, on the other hand, are subjected to the actions of the various 
mannosidases and transferases as they traverse the Golgi stack.
KEY;
Carbohydrate residues :- 
A - glucose 
A - fucose 
•  - m annose 
Processing enzymes :- 
G - glucosidase
O - galactose
□ - sialic acid
■ - N-acetylglucosamine
M - mannosidase 
N - N-acetylglucosaminyl-l-phosphodiester-a-N-acetylglucosaminidase 
Processing inhibitors
CSP - castanospermine SW - swainsonine
dNM - 1-deoxynojirimycin dMM - 1-deoxymannojirimycin
r e r \
GI
(CSP/dNM) 
-asn-x-ser/thr-
(CSP/dNM)
r .u«u]
I PM
GOLGI
2UDP
(dMM)
medial
UDP-
trans
2UDP-0 2CMP-D
2CMP
pu GDP-A
2UDP
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rough endoplasmic reticulum, at least one a(l,2)-linked mannose residue is 
specifically trimmed by an a-mannosidase (Bischoff and Komfeld, 1983).
The deglucosylated glycoproteins are then transported into the Golgi 
apparatus. This interorganelle movement occurs by means of vesicles which pinch 
off the endoplasmic reticulum and fuse with the Golgi membranes (Jamieson and 
Palade, 1967). However, since the rate of glycoprotein movement varies between 
protein species (Lodish et al., 1983; Gabel and Komfeld, 1984), a receptor- 
mediated transport mechanism is also thought to be involved. This notion is further 
supported by the finding that maturation of some glycoproteins into the Golgi 
apparatus is blocked when the endoplasmic reticulum deglucosylation process is 
inhibited (Gross et al., 1983; Lodish and Kong, 1984; Lemansky et al., 1984). 
Alternatively, the glucose removal may also be necessary for the glycoproteins to 
mature to a correct conformation (Schlesinger et al., 1984).
The Golgi apparatus can be separated into at least three distinct functional 
compartments based on the localizations of the distinct N-linked oligosaccharide 
processing activities (reviewed by Farquhar, 1985). Independent studies utilizing 
different experimental approaches have demonstrated that the processing of r e ­
linked oligosaccharides occurs sequentially as the glycoproteins traverse the Golgi 
apparatus. Upon entry into the cisternal face of the Golgi stack (i.e. the cis 
compartment), a subset of glycoproteins that are destined for the lysosome undergo 
specific mannose phosphorylation catalyzed by the enzyme N-acetylglucosaminyl- 
1-phosphotransferase (Hasilik etal., 1981; Reitman and Komfeld, 1981). This is 
followed by the action of another enzyme, N-acetylglucosaminyl-l-phosphodiester- 
a-N-acetyl-glucosaminidase (Varki and Komfeld, 1980 and 1981), that cleaves off 
the terminal N-acetylglucosamine residues (see figure 2). The mannose-6- 
phosphate configurations acquired through these reactions act as specific ligands 
that interact with the intracellular mannose-6-phosphate receptors and facilitate the
glycoprotein transport to the lysosome (reviewed by von Figura and Hasilik, 
1986). As these phosphorylated N-linked oligosaccharide moieties of lysosomal 
glycoproteins are not subject to further processing in the late Golgi compartments, 
the mannose phosphorylation may also confer protection against further enzymatic 
action.
Unlike the lysosomal hydrolases, secretory and membrane-associated 
glycoproteins are firstly subjected to demannosylation processes. The trimming of 
terminal a(l,2)-mannose units of the N-linked oligosaccharide by the enzyme 
mannosidase I is believed to occur in the cis or the medial compartment of the 
Golgi apparatus (Rothman et al., 1984a and 1984b). This is followed by transfer 
of one N-acetylglucosamine residue in the medial Golgi compartment (Dunphy and 
Rothman, 1983), a process of which is catalyzed by N-acetylglucosaminyl- 
transferase I (Harpaz and Schachter, 1980a; Oppenheimer et al., 1981). Also 
within the medial compartment of the Golgi apparatus, further removal of two 
mannose residues by the a(l,3)- and a(l,6)-specific mannosidase II (Tulsiani et 
al., 1982; Tulsiani and Touster, 1983) and the transfer of another one or two N- 
acetylglucosamine residues by N-acetylglucosaminyltransferase II takes place 
(Harpaz and Schachter, 1980a; Mendicino etal., 1981).
The action of the N-acetylglucosaminyltransferase II forms the initiation 
of the complex conversion reaction. Before being deposited into the plasma 
membrane or secreted into the extracellular environment, many oligosaccharides of 
glycoprotein are finally transformed into the "complex type" structure. This 
conversion is generally followed by the additions of one fucose unit to each of the 
innermost N-acetylglucosamine residues of the N-linked oligosaccharide chains 
(Longmore and Schachter et al., 1982), and the subsequent transfer of galactose 
and sialic acid units, sequentially, to the terminal carbohydrate residues (Beyer et 
al., 1981). The transferases that catalyze the two latter reactions have been
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localized to the trans cistemae of the Golgi stack (Dunphy etal., 1981; Roth and 
Berger, 1982; Slot and Geuze, 1983). Transformation to the "complex type" N- 
linked structures is a rapid process and occurs immediately before the glycoproteins 
exit into the extracellular environment (Peyrieras et al., 1983).
1.2.3. Structural Diversity of N-Linked Oligosaccharides.
Studies locating the specific site of the various enzymes involved in the 
processing of N-linked oligosaccharide chains have clearly indicated that 
modifications of the carbohydrate moieties of glycoproteins occur as they traverse 
the Golgi apparatus. It is now apparent that the Golgi apparatus is really a well 
organized "processing factory" where a great variety of specific and systematic 
modification reactions occur. Characterization of the structures of N-linked 
oligosaccharide moieties of glycoproteins have, however, demonstrated the 
existence of diverse structural forms (Yamashita etal., 1983). A few examples of 
these variations are illustrated in figure 3.
Several distinct structural forms have also been shown to exist between 
the N-linked oligosaccharides of the same glycoprotein. One common example is 
the monomeric IgM molecule, in which two of its five N-linked oligosaccharide 
moieties are able to escape complex-conversion and retain their high mannose 
structures (Shimizu et al., 1971). Such partial transformation implicates the 
importance of the protein conformations in the determination of the glycoproteins 
modification.
The extent of the complex conversion reaction is another factor that 
contributes to the different carbohydrate configurations. Perhaps the best example 
to illustrate this phenomenon comes from the report by Parekh et al., 1985, which 
demonstrates that the IgG of human serum may consist of at least 30 different
7
Figure 3. Structural diversity of N-linked oligosaccharides.
Structures of selective N-linked oligosaccharides of glycoproteins are schematically 
illustrated;
a) Precursor-type N-linked oligosaccharide.
b) High mannose-type N-linked oligosaccharide of human IgM.
c) Hybrid-type N-linked oligosaccharide of VSV G protein.
d) Monoantennary N-linked oligosaccharide of human urinary glycoprotein.
e) Biantennary complex-type N-linked oligosaccharide of human IgG.
f) Triantennary complex-type N-linked oligosaccharide of VSV G protein.
g) Tetraantennary complex-type N-linked oligosaccharide of VSV G protein.
Note that, with the exception of (d), all other N-linked oligosaccharides possess 
common "core" carbohydrate structure (i.e., N-acetylglucosamine2 Mannose3). For 
references, see Yamashita et al., 1983 and Komfeld and Komfeld, 1985).
KEY:
A - glucose 
A - fucose , □ - sialic acid
O - galactose
•  - mannose ■ - N-acetylglucosamine
a l,2
a l,3
a l,3
a l,2  J a l,2a l,2
a l,2a l,2  a l,6 a l,3ra l t3 a l,2a l ,6
a l,3
a l,3 a l,6 al,3 a l,6a l ,6
V  1,4 
pi,4pl ,4
P1.4PM
(a) (b) (c) (d)
Pl,3 |P l,3a2,3 I a2,3 I a2,3
pl,4 | pi,4 I Pl,4 |p l,4
Pl ,2 pl ,2 Pl,2 1,2
a l ,3a l,6 a l,6a l ,6 a l,3 a l,3
Pl,4
pl,4 Pl.4 pl,4
a l,6 al,6i
(e) (0 (g )
8
complex-type biantennary oligosaccharide structures. In addition, it was also 
reported that approximately 5% of the total IgG population is disialylated; a further 
2 0 % exists as monosialylated forms with the vast remainder having neutral 
structures. Interestingly, such structural heterogeneity is not confined to the 
polyclonal IgG population. Relatively similar proportions have also been observed 
in monoclonal immunoglobulins secreted from a hybridoma cell line (Radamacher 
and Dwek, 1983). This observation certainly implies that the structural 
heterogeneity is more likely to arise from random processing and not by means of 
any specific regulatory mechanism in individual cells. Thus, it seems reasonable to 
propose that N-linked oligosaccharides are only modified if they happen to 
encounter the various intracellular site-specific processing enzymes in their route to 
exocytosis.
In certain cell types, further structural variations have been detected in 
which a "bisecting" N-acetylglucosamine has been attached to the core p -mannose 
residue. These cells have been shown to possess an enzyme, N-acetyl- 
glucosaminyltransferase III, that specifically transfers one N-acetylglucosamine 
molecule to the core p-mannose (Harpaz and Schachter, 1980b). This reaction 
causes inhibition of the subsequent action of the mannosidase n ,  which then, leads 
to the formation of the "hybrid-type" N-linked structure (see oligosaccharide 
structure c in figure 3; Harpaz and Schachter, 1980b).
In fact, a vast majority of the final oligosaccharide structures are 
dependent on such a regulatory mechanism, where order and specificity of the 
structures of substrate molecules are absolute requirements for further modification 
reactions. For instance, it has been shown that fucosylation and sialylation of 
asialotransferrin are two mutually exclusive reactions, i.e., a prior action of one 
enzyme will subsequently inhibit the other (Paulson et al., 1978; Beyer et al., 
1979). Similarly, galactosylation of terminal carbohydrate chains would only occur
if a prior addition of a ( l,6 )-linked N-acetylglucosamine residues has taken place 
(Blacken et al.f 1982). A more detailed discussion of these regulatory mechanisms 
has been reviewed by Komfeld and Komfeld (1985).
Diversity that arises from the structures of N-linked oligosaccharides from 
different glycoproteins is even more pronounced. Biochemical analyses have 
demonstrated that N-linked oligosaccharides of glycoproteins can exist as mono-, 
bi-, tri- and tetraantennary structures (see figure 3). Structural conformations in 
these cases are more likely to be regulated by specific endogenous branching 
enzymes.
Structural variations may also arise from other post-translational 
modifications of the asparagine-linked oligosaccharides. The more common 
reactions include the phosphorylation of mannose residues (see section 1 .2 .2 ) and 
the O-sulphation of N-acetylhexosamine (Prehm et al., 1979; Parsons and Pierce, 
1980; Edge and Spiro, 1984) or mannose units (Freeze et al., 1984). While the 
phosphorylation of mannose residues has been shown to be involved in the 
transport mechanism (von Figura and Hasilik, 1986), the function of sulphation of 
carbohydrate moieties remains unknown.
Although ample evidence has demonstrated the existence of 
microheterogeneity in the structures of N-linked oligosaccharides chains, no general 
physiological role has been attributed to this diversity. However, together with the 
other carbohydrate heterogeneity from other types of glycoproteins and 
glycoconjugates (Yamashita et al., 1983), these variations in the structures of 
carbohydrate residues certainly provide a wide spectrum of epitopes for specific 
receptor-ligand interactions.
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1.3.1. Inhibitors of N-GIycosylation.
Inhibitors of N-glycosylation are commonly used in studies assessing the 
functional roles of N-linked carbohydrate moieties of glycoproteins. Development 
of assays for measuring the biosynthesis of lipid-linked oligosaccharides and 
monosaccharides has provided the means to investigate the mechanisms of actions 
of the inhibitors and the exact step(s) which they inhibit (Behrens and Tabora, 
1978). Such understanding is imperative in order to critically evaluate any 
experimental data obtained from studies involving use of glycosylation inhibitors. 
Currently, two distinct categories of inhibitors of N-glycosylation have been 
recognized; sugar analogues and antibiotics.
1.3.1.1. 2-Deoxy-D-GIucose.
One of the early inhibitors of N-glycosylation utilized in biochemical 
analyses of protein glycosylation was 2-deoxy-D-glucose (dGlc) (Farkas et al., 
1969). In order to exert its inhibitory effect, this sugar analogue must be 
metabolically converted into its nucleotide esters, GDP- and UDP-dGlc (Schmidt 
et al., 1974 and 1976; Datema et al.y 1981).
The effects of this drug are numerous. Both the nucleotide esters GDP- 
and UDP-dGlc inhibit the formation of Glc-P-Dol by trapping of dolichol 
phosphate (Dol-P) as dGlc-P-Dol (Datema and Schwarz, 1978; Datema et al.y
1981). This product would subsequently, inhibit the glucosylation of Manp(N- 
GlcNAc)2 -P-P-Dol by incorporating dGlc instead of glucose (Datema et al.,
1981). GDP-dGlc has also been demonstrated to inhibit the assembly of the lipid- 
linked oligosaccharide by incorporation of the sugar analogue in place of mannose 
(Schwarz et al.y 1978).
Experiments in cell-free systems have demonstrated that if dGlc was
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incorporated instead of mannose into the lipid-linked oligosaccharide, transfer of 
the carbohydrate moiety to the nascent polypeptide could not occur (Datema and 
Schwarz, 1978). Paradoxically, labelled dGlc at non-inhibitory concentrations, has 
been shown to be incorporated into glycoproteins (Kaluza et al,, 1973; Steiner et 
al., 1973).
In other studies, data obtained from utilization of this compound has 
proved to be doubtful. For instance, in yeast, this sugar analogue appears to inhibit 
the secretion of newly synthesized mannan-associated enzymes (Farkas et al,, 
1970; Kuo and Lampen, 1972). However, subsequent analysis later revealed that 
the reduced rate of secretion is due to the decreased rate of synthesis of the enzyme, 
and not due to non-glycosylation of the macromolecules (Kratky et al., 1975).
A similar situation also arises in experiments studying the 
immunoglobulin system. Melchers (1973) has reported that secretion of IgG from 
MOPC 21 cell line is blocked in the presence of this sugar analogue and suggested 
that it was a result of the absence of carbohydrate molecules. However, studies 
using tunicamycin, which is also an inhibitor of N-glycosylation (see section
1.3.1.2), have all indicated that the secretion of this isotype of immunoglobulin is 
not significantly reduced in the non-glycosylated state (see section 1.4.1).
1.3.1.2. Tunicamycin.
The structure of tunicamycin is illustrated in figure 7, panel a. 
Tunicamycin was firstly extracted from Streptomyces lysosuperificus as an 
antibiotic with antiviral activity. Subsequent analysis later revealed that the antibiotic 
also inhibits the replication of gram-positive bacteria, fungi and yeast, and more 
importantly, prevents the N-glycosylation of nascent polypeptides (Takatsuki et 
al,, 1971; Takatsuki and Tamura, 1971a and b; Takatsuki etal., 1972). Unlike 2- 
deoxy-D-glucose, this inhibitor of N-glycosylation does not interfere with either
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sugar or nucleotide metabolism (Kuo and Lampen, 1974; Tkacz and Lampen, 
1975) and is not metabolizable under either in vivo or in vitro conditions (Kuo 
and Lampen, 1976).
The mechanism of action of tunicamycin has been extensively investigated 
by a number of workers. The drug has been shown to specifically inhibit the 
synthesis of N-acetylglucosaminylpyrophosphorylpolyisoprenol, the first product 
of the lipid-linked oligosaccharide formation pathway (Tkacz and Lampefi, 1975; 
Takatsuki et al., 1975), but has no effect on the subsequent steps of the chain 
elongation reactions or upon the final transfer of oligosaccharide to nascent 
polypeptides (Lehle and Tanner, 1976; Struck and Lennarz, 1977). This specific 
inhibition has been shown to occur by non-competitive and irreversible interaction 
of tunicamycin with UDP-GlcNAc:dolichyl phosphate GlcNAc-1-phosphate 
transferase, the enzyme that catalyzes the first step in the biosynthetic pathway of 
the lipid-linked oligosaccharide complex (Heifetz et al., 1979).
Apart from its high-affinity interaction with the enzyme UDP- 
GlcNAc:dolichyl phosphate GlcNAc-1-phosphate transferase, tunicamycin has also 
been suggested to possess another intracellular binding site, with a much lower 
affinity (Heifetz et al., 1979). An earlier report by Kuo and Lampen (1974) 
demonstrated that the binding of tunicamycin to yeast protoplasts can be inhibited 
by the inclusion of phospholipid with an unsaturated fatty acid moiety. Thus, it was 
speculated that tunicamycin may interact non-specifically with a lipophilic 
component of a cellular membrane, in addition to its high affinity binding to UDP- 
GlcNAcrdolichyl phosphate GlcNAc-1-phosphate transferase.
Tunicamycin is, however, not without cytotoxic effects. Its presence has 
been demonstrated to caused impairment in the synthesis of macromolecules and
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induces the degradation of cellular RNA and DNA (Takatsuki and Tamura, 1971b; 
and Takatsuki et al., 1971 and 1972). The mechanisms involved in these reactions 
are not defined. Although there is no direct evidence, it is believed that such 
cytotoxicity is due to secondary effects resulting from interference of the inhibitor 
with other cellular reactions, and not a direct drug-induced response (Struck and 
Lennarz, 1980; this thesis).
One of the main drawbacks in studies employing inhibitors of N- 
glycosylation is the difficulty in deducing the precise effect resulting from non-N- 
glycosylation against a background of sequalae that are indirectly induced by the 
drug. Thus, in this respect, tunicamycin offers certain advantages over 2 -deoxy-D- 
glucose or other sugar analogues due to its non-involvement in general cellular 
metabolism. However, tunicamycin itself is not without side-effects. One example 
is its inhibition of cellular RNA, DNA and protein synthesis. Thus, experimental 
data that arise from utilization of this antibiotic may, under certain circumstances, 
prove to be equally erroneous especially when a long-term exposure to the drug is 
required.
1.3.2. Inhibitors of N-Linked Oligosaccharide Processing.
Discoveries of inhibitors of N-linked oligosaccharide processing events 
are a recent advance (reviewed by Fuhrmann et al., 1985 and Elbein, 1987). Their 
use in experimental analysis would certainly provide additional information on the 
biological role of oligosaccharide processing (see section 1.4). Two classes of 
processing inhibitors are currently known; sugar analogues, that are derived from 
microorganisms, and plant alkaloids. Both sets of inhibitors function by mimicking 
the substrate molecules of the specific trimming enzymes. The biochemistry of the 
four selective processing inhibitors employed in this study (the structures of which 
are illustrated in figure 4) are discussed briefly below.
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Figure 4. Structures of N-linked oligosaccharide processing inhibitors.
Structures of N-linked oligosaccharide processing inhibitors that are used in this 
study are illustrated. The specific actions of the inhibitors in the N-linked 
oligosaccharide processing pathway are schematically illustrated in figure 2. CSP 
and dNM inhibit glucosidase I and II; dMM, mannosidase Ia/b and SW, 
mannosidase II. For references, see sections 1.3.2.1 - 1.3.2.4.
HO OH
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1.3.2.1. Castanospermine (CSP).
Castanospermine (1,6,7,8,-tetrahydroxyoctahydroindolizidine) was first 
isolated from the plant, Castanospermum australe (Hohenschutz et al., 1981). It 
has been shown to inhibit the action of both a- and p-glucosidase (Saul et a/.,
1983), and the processing of influenza viral haemagglutinin (Pan et al., 1983), 
soybean cell glycoproteins (Hori et al., 1984) and human hepatoma cell 
glycoproteins (Sasak et al., 1985). Castanospermine inhibits both the actions of 
glucosidase I and II of the N-linked oligosaccharide processing pathway (Pan et 
al., 1983; Sasak etal., 1985; Szumilo etal., 1986).
Bio-gel P4 chromatographic resolution of the Endo H-cleaved 
carbohydrate, synthesized in the presence of castanospermine, has revealed that the 
majority of the oligosaccharide possess hexosejQ-GlcNAc structures and enzymic 
methods have identified the oligosaccharides as being mostly of the 
Glc3Man7GlcNAc configuration (Pan et al., 1983). This strongly suggests that the 
carbohydrate chains are still subjected to further trimming processes despite having 
intact glucose residues on one of their branched terminals.
1.3.2.2. 1-Deoxynojirimycin (dNM).
1-Deoxynojirimycin (dNM) also inhibits both the glucose trimming 
enzymes in the N-linked oligosaccharide processing pathway (see figure 2). 
However, its specificity and magnitude of inhibition appear to differ according to 
species. In yeast, it has been shown that the I50  (i.e., the concentration of inhibitor 
achieving a 50% inhibition of enzyme activity) for glucosidase I and II, are 20pM 
and 2pM, respectively (Saunier et al., 1982). The converse occurs in calf liver 
cells, in which the I50  for glucosidase II ( 20pM) is much higher than that for 
glucosidase I (3pM) (Hettkamp et al., 1982).
At lOmM concentration, dNM has been demonstrated to inhibit the N-
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glycosylation process (Gross et al> 1983). This is apparent from the higher Mr 
band of the inhibitor-treated samples analyzed by SDS-polyacrylamide gel 
electrophoresis. Like most other sugar analogues, dNM may be involved in other 
cellular metabolic pathways, although no report on this aspect has yet been 
documented.
Because of its inhibition of both glucosidase I and II activities of the 
oligosaccharide processing pathway, the carbohydrate structures that are formed in 
the presence of this drug may be expected to consist of a mixture of 
oligosaccharides with different number of glucose residues. This has indeed been 
confirmed by resolution of the Endo H-cleaved oligosaccharides by Bio-gel P4 
chromatography (Gross et al., 1983). Furthermore, the presence of 
oligosaccharides that have been subjected to further mannose trimmings was also 
detected. Other evidence has indicated that at least part of the oligosaccharide may 
have been subjected to complex conversion (Peyrieras et al., 1983).
1.3.2.3. 1-Deoxymannojirimydn (dMM).
The mannose analogue of dNM, 1-deoxymannojirimycin (dMM) or 1,5- 
dideoxy-l,5,-imino-D-mannitol, has been synthesized and shown to be an inhibitor 
of the mannosidase Ia/b of the N-linked oligosaccharide processing pathway 
(Fuhrmann et al., 1984). Structural analysis of the carbohydrate chains of IgM and 
IgD synthesized in the presence of this amino-sugar has demonstrated about 70% of 
the high-mannose oligosaccharides are of the Ma^GlcNAcj structure. Unlike in 
the case of dNM, these oligosaccharides have been demonstrated not to undergo 
further processing as indicated by N-acetylneuraminidase digestion analysis.
1.3.2.4. Swainsonine (SW).
The final N-linked oligosaccharide trimming enzyme of the Golgi
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apparatus has been shown to be inhibited by an alkaloid, swainsonine (8 a- 
indolizidine-l,2,8-triol), firstly isolated from a leguminous plant, Swainsona 
canescens (Colegate et al.y 1979). Swainsonine, which also inhibits the 
mannosidases of the lysosomes (Dorling et al., 1980), was shown to act only on 
the late mannosidase II enzyme, without affecting the mannosidase Ia/b (Tulsiani et 
al.y 1982). N-linked oligosaccharides produced in the presence of this inhibitor 
appear to be of the hybrid-type (Tulsiani et al., 1982). Since inhibition of 
mannosidase II only affects one half of the carbohydrate moiety (see figure 2), the 
other is therefore normally processed to the complex form.
1.4. Roles of Carbohydrate Moieties of Glycoproteins.
N-linked oligosaccharide moieties of glycoproteins have been implicated 
in many diverse functions. Participation of the carbohydrate moieties could be seen 
either by their contribution to the optimal structural or physicochemical properties of 
the glycoproteins, or by regulating their transport via receptor-mediated 
mechanisms. These diverse roles of N-linked oligosaccharide moieties of 
glycoproteins are elaborated in the following discussion.
1.4.1. Facilitating Secretion.
An hypothesis of carbohydrate moieties as controlling elements in the 
secretion of glycoproteins has been advanced. In an attempt to generalize the 
functional role of the carbohydrate structures of glycoproteins, Eylar (1965) has 
forwarded an hypothesis which regards carbohydrate moieties as chemical markers 
that discriminate secretory and intracellular proteins. In addition, it was also 
envisaged that there exist receptors for these carbohydrate units in carriers or 
cellular membranes that, upon interaction with the glycoproteins, will facilitate their 
export.
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This hypothesis is still open to criticism. To date, no such membrane or 
vesicular receptors have been discovered, and more importantly, inhibition of N- 
glycosylation only affects the transport of certain glycoproteins (see tables 1 and 2 ). 
The inhibitory effect observed on the transport of the non-N-glycosylated 
glycoproteins provides some support for Eylar's hypothesis and implicates the role 
played by the carbohydrate moieties in the export of the macromolecules. However, 
the fact that other non-N-glycosylated glycoproteins are able to escape inhibition of 
secretion suggests a more complex situation. The selective inhibition of specific 
non-N-glycosylated glycoproteins has also been shown to occur in a hybridoma cell 
line that simultaneously secretes both IgG and IgM; while the secretion of the non- 
N-glycosylated IgG is efficiently maintained, the export of the non-N-glycosylated 
IgM is profoundly inhibited (Blatt and Haimovich, 1981). Hence, the possibility 
that the selective inhibition is due to different secretory mechanisms adopted by 
individual cell types is apparently ruled out This observation would also negate the 
notion that carbohydrate moieties are the sole controlling element in the secretion of 
glycoproteins. Other hypotheses that could account for this intriguing selective 
inhibitory transport phenomenon are therefore proposed;
1) there is an alternative secretion controlling mechanism that non-N- 
glycosylated glycoproteins could employ to secure export (e.g., 
sulphation on tyrosine residues, Baeuerie and Huttner, 1984) and/or,
2 ) other parameters are involved in the control of glycoprotein secretion, 
e.g., solubility, size, the extent of glycosylation and the presence of other 
types of carbohydrate moieties.
The first postulate is somewhat weak since
it arises from a single experimental observation. When the glycosylation of murine 
IgG2a is inhibited, the molecules have been shown to be sulphated at tyrosine
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Table 1. Effects of tunicamycin on secretory glycoproteins.
Glycoproteins Result References
Invertase and acid 
phosphatase of yeast
secretion inhibited Kuo and Lampen, 1976
IgA of MOPC 315 secretion inhibited; 
blocked within RER
Hickman et al., 1977
IgE ofIR 162 secretion inhibited Hickman et al., 1977
IgA of 5 mouse plasma­
cytoma lines and IgM of 
MOPC 104E
secretion inhibited Hickman and Komfeld, 
1978
IgG of 6  mouse plasma­
cytoma lines
secretion not affected Hickman and Komfeld, 
1978
Fibronectin of chick 
embryo fibroblast
secretion not affected; 
enhanced proteolysis
Olden et al., 1978
Rat liver transferrin and 
chick liver apoprotein B
secretion not affected Struck era/., 1978
Ovalbumin of oviduct secretion not affected Keller and Swank, 1978
Carboxypeptidase Y of 
yeast
secretion not affected Hasilik and Tanner, 1978
Mouse L cell interferon secretion not affected Fujisawa et al., 1978
Human fibroblast 
interferon
secretion not affected Mizrahi et al., 1978
Procollagen of chick 
embryo fibroblast
secretion not affected Duksin and Bomstein, 1979
IgM of X63/38C-13 secretion inhibited Blatt and Haimovich, 1981
IgG of X63/38C-13 secretion not affected Blatt and Haimovich, 1981
IgA of DAKIKI Arosros- 
1 and IgM of BJAB
secretion inhibited Cushley etal., 1982
IgG of EB-4, Bee 11 and 
MAJA
secretion not affected Cushley etal., 1982
IgD of B1.88 secretion not affected Vasilov and Ploegh, 1982
2 0
Table 2. Effects of tunicamycin on plasma membrane glycoproteins.
Glycoproteins Result References
Sindbis viral 
glycoproteins
membrane insertion 
inhibited; enhanced 
proteolysis
Schwarz etal., 1976
Semliki viral 
glycoproteins
membrane insertion 
inhibited
Leavitt et al., 1977
Acetylcholine receptor 
in muscle cells
transport not affected; 
enhanced proteolysis
Trowbridge etal., 1978
Vesicular stomatitis 
viral G protein
membrane insertion not 
affected
Gibson etal., 1978
IgA of MOPC 315 membrane insertion not 
affected
Hickman and Wong-Yip, 
1979
Erythrocyte glyco- 
phorin
membrane insertion not 
affected
Gahmberg et al., 1980
HLA-A and -B antigens 
of JY
membrane insertion not 
affected
Ploegh etal., 1981
IgM of W279 membrane insertion not 
affected
Sibley and Wagner, 1981
Transferrin receptor of 
CCRF-CEM
membrane insertion not 
affected
Omaiy and Trowbridge, 
1981
LDL receptor of human 
fibroblasts
membrane insertion 
inhibited
Chatteijee et al., 1981
IgA of DAKIKI-Aios- 
ros-1 and IgM of BJAB 
and D AUDI
membrane insertion 
inhibited
Cushley et al., 1981
Murine leukemia viral 
glycoproteins
membrane insertion 
inhibited
Polonoff et al., 1982
IgM of D AUDI membrane insertion 
inhibited
Kubo and Pelanne, 1983
Asialoglycoprotein 
receptor of HepG-2
membrane insertion not 
affected
Breitfeld et al., 1984
Mouse hepatitis viral 
glycoprotein E-2
membrane insertion 
inhibited
Repp et al., 1985
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residues (Baeuerle and Huttner, 1984). Although sulphation is a widespread 
occurrence, its function is still unknown (Huttner, 1982). However, with the 
exception of a single case (Liu and Baenziger, 1985), all other reported proteins that 
possess tyrosine sulphated residues are destined for secretion. In addition, 
comparative analysis on the plasma proteins and the proteins from various tissues 
have also demonstrated that the former has a much higher level of tyrosine sulphate 
content (Hille et al., 1984). These observations strongly implicate the involvement 
of tyrosine sulphation as a secretory mechanism. Thus, in the case of the non-N- 
glycosylated IgGs, sulphation has been suggested as an alternative mechanism in 
ensuring their export (Baeuerle and Huttner, 1984).
The second scenario is best illustrated in the immunoglobulin system. The 
data of Hickman and Komfeld (1978) have clearly demonstrated that the extent of 
inhibition of immunoglobulin secretion correlates with the carbohydrate content and 
the overall molecular size of the various immunoglobulin isotypes. Accordingly, the 
secretion of the IgG, which is a monomer with (in most cases) a single N-linked 
oligosaccharide moiety on each of its gamma chains, is not significantly reduced 
(Hickman and Komfeld, 1978). In addition, the absence of carbohydrate moieties 
have also been demonstrated to cause an alteration on the physicochemical property 
of the proteins as well as decreasing their stability (Tarentino et al., 1974; Chu et 
al., 1978; Hickman and Wong-Yip, 1979). Such changes in conformation and 
solubility would be most likely to have a greater effect on the highly glycosylated 
molecules like IgA, IgM and IgE, although other factors like the primary structure 
of the protein and the location of the oligosaccharide structures may be equally 
important. The presence of other types of carbohydrate moieties, e.g., O-linked 
oligosaccharide chains of IgA or IgD (Dawson and Clamp, 1968; Jefferis et al., 
1975), not affected by tunicamycin could also contribute to the extent of blockade 
of the glycoprotein secretion.
2 2
1.4.2. Facilitating Intracellular Routing.
While secretion involves the ultimate export of macromolecules, 
carbohydrate moieties could also play a role in the sorting and the regulation of 
intracellular trafficking of glycoproteins. N-linked oligosaccharides of 
glycoproteins are extensively processed as they traverse the Golgi apparatus (see 
section 1.2.2). The oligosaccharide processing may play a role in acquiring a 
specific configuration involved in trafficking mechanism. Indeed, transport of 
lysosomal glycoproteins have been shown to be regulated by such a mechanism; via 
the mannose-6 -phosphate residues of their N-linked oligosaccharide chains (see 
section 1.2.2). The involvement of carbohydrate moieties of secretory or 
membrane-associated proteins, on the other hand, is less definite.
By utilizing specific processing inhibitors, numerous studies have shown 
that while the trimming of terminal glucose residues in some glycoproteins is 
essential for their efficient maturation from the rough endoplasmic reticulum to the 
Golgi apparatus, such processing is less crucial in other glycoproteins (see tables 3 
and 4). Inhibition of mannosidases of the Golgi apparatus have, however, been 
consistently reported to have no inhibitory effect on the kinetics of the export of 
glycoproteins (see tables 3 and 4).
The above selective inhibitory phenomena would again indicate different 
trafficking mechanisms for individual glycoproteins unless the regulation of 
transport is dependent upon some other controlling parameters. Currently, at least 
two separate exocytic transport pathways are recognized (reviewed by Farquhar, 
1985). Secretory proteins could either be transported via a regulatory (i.e., 
dependent on an appropriate signal) or a constitutive mechanism (i.e., continually 
maintained) (Moore and Kelly, 1985). These distinct transport mechanisms provide 
excellent rationalization of the above selective inhibitory phenomena. While the
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Table 3. Effects of N-linked oligosaccharide processing inhibitors on secretory
glycoproteins.
Glycoproteins Processing
Inhibitor
Result References
IgDofB1.88 dNM secretion
inhibited
Peyrieras et al., 
1983
IgM of B 1.8m. dNM secretion not 
affected
Peyrieras et al., 
1983
IgM of B1 .8 m- and IgD 
of B 1.88
SW secretion not 
affected
Peyrieras et al., 
1983
a i -antichymotryp sin and 
cq-antitrypsin of HepG-2
dNM secretion
inhibited
Lodish and Kong, 
1984
Transferrin, albumin and 
glycoprotein C3 of HepG-2
dNM secretion not 
affected
Lodish and Kong, 
1984
IgM of B 1.8m- and IgD 
of B 1.88
dMM secretion not 
affected
Fuhrmann etal., 
1984
Caeruloplasmin and 
oq-antitrypsin of HepG-2
CSP secretion
inhibited
Sasak et al., 1985
a-acid glycoprotein and 
a-proteinase inhibitor 
of rat hepatocytes
dMM transport not 
affected
Gross et a/., 1985
Secretoiy glycoproteins 
of HepG-2
SW transport and
secretion
accelerated
Yeo et al., 1985
a-acid glycoprotein and 
a-proteinase inhibitor 
of rat hepatocytes
Methyl-dNM 
dNM and CSP
transport not 
affected
Gross et al., 1986
Thyroglobulin of 
porcine thyroid cells
dNM and SW secretion not 
affected
Franc et al., 1986
IgE of a mouse 
hybridoma cells
CSP, methyl- 
dNM and SW
secretion not 
affected
Granato and 
Neeser, 1987
IgM of 4A3 and IgG 
of I1A1.4
CSP, dNM, 
dMM and SW
secretion not 
affected
Has him and 
Cushley, 1987b,c
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Table 4. Effects of N-linked oligosaccharide processing inhibitors on plasma
membrane glycoproteins.
Glycoproteins Processing
Inhibitor
Result References
Vesicular stomatitis 
viral glycoproteins
SW membrane insertion 
not affected
Kang and Elbein. 
1982
HLA-A, -B and -C 
antigens of B AU
dNM and dMM membrane insertion 
not affected
Burke et al 
1984
Asialoglycoprotein 
receptor of HepG-2
SW membrane insertion 
not affected
Breitfeld et al.y 
1984
Influenza viral 
glycoproteins
dMM membrane insertion 
not affected
Elbein et al 
1984
Rous sarcoma viral 
glycoproteins
dMM and SW membrane insertion 
not affected
Bosch et al 
1985
Mouse hepatitis viral 
glycoprotein E-2
methyl-dNM 
and CSP
membrane insertion 
inhibited
Repp et al 
1985
Mouse hepatitis viral 
glycoprotein E-2
dMM and SW membrane insertion 
not affected
Repp et al 
1985
Feline sarcoma viral 
oncogene products
methyl-dNM 
and CSP
membrane insertion 
inhibited
Nichols et al., 
1985
Feline sarcoma viral 
oncogene products
SW membrane insertion 
not affected
Nichols et al., 
1985
Insulin and Insulin­
like growth factor I 
receptors of IM-9
SW membrane insertion 
not affected
Duronio et al., 
1986
Key; dNM: 1-deoxynojirimycin dMM: 1-deoxymannojirimycin
CSP: Castanospermine SW: Swainsonine
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transport of the inhibited glycoproteins reflects that of the regulated-type 
mechanism, that of the non-inhibited glycoproteins would presumably be of the 
constitutive-type.
In the case of immunoglobulins, further controversy surrounds the 
different effects reported on the transport and ultimate insertion of the membrane- 
form non-N-glycosylated IgA and IgM (see table 2). While certain data exhibit no 
interference in the membrane localization of the surface molecules (Hickman and 
Wong-Yip, 1979; Sibley and Wagner, 1981), others demonstrate inhibition 
(Cushley, 1981; Yuan, 1982; Kubo and Pelanne, 1983; Sitia et al., 1984). Much 
of these discrepancies appear to arise from the different experimental approaches 
that were adopted, and several arguments have already been proposed to counter the 
apparent detection of the non-N-glycosylated immunoglobulins at the plasma 
membrane (Cushley, 1981; Yuan, 1982; Kubo and Pelanne, 1983; Sitia etal.,
1984), i.e., there is no evidence to indicate that the immunoglobulins detected on 
the cell surface are indeed the membrane-bound form and are of the non-N- 
glycosylated type.
However, the distinct effects that are observed would suggest 
involvement of different transport mechanisms or the existence of separate transport 
pathways followed by the secreted and membrane-bound immunoglobulins. 
Indeed, the possibility of a single cell type having two separate exocytic pathways 
has been demonstrated to occur in a mouse pituitary tumour cell line, i.e., by 
possessing both the constitutive and regulatory mechanisms (Gumbiner and Kelly,
1982). Although the secretory mechanism in plasma cells has been implicated to be 
of the constitutive type (Tartakoff and Vassalli, 1977 and 1978), such a mechanism 
could perhaps account only for the major synthetic products of the cells, i.e., the 
immunoglobulins, or alternatively, multiple constitutive intracellular transport 
channels could be in existence. Thus, it is still highly possible that membrane-
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bound immunoglobulins could be transported and deposited via a different pathway 
of similar or dissimilar mechanisms.
In further support of this hypothesis, the work of Strous and Lodish 
(1980) have demonstrated that plasma membrane glycoproteins may be synthesized 
at twice the rate of a secreted glycoprotein, implying that the two processes have to 
differ at some stage. In an extended study, they have also reported that the 
maturation of secreted proteins from the rough endoplasmic reticulum to the Golgi 
apparatus in human hepatoma HepG-2 cells occur at different and characteristic 
rates (Lodish et al„ 1983).
Currently, the accepted view on the structures of the distinct monomeric 
secretory and membrane forms of a single immunoglobulin isotype is that the latter 
slightly differ by possessing an extra hydrophobic peptide sequence at the carboxy 
termini of its heavy chains, that functions as an anchorage in the plasma membrane 
(Williams et al.> 1978; Singer etal., 1980; Cushley, 1981; Cushley et al., 1982). 
If the controversial immunoglobulins detected on the cell surface are indeed the 
non-N-glycosylated membrane-bound form, then the obvious implication would be 
that the hydrophobic sequence of the cell surface immunoglobulins is somehow 
involved in the prevention of blockade at the membrane of the rough endoplasmic 
reticulum.
Alternatively, the selective inhibition of secretory IgM and IgA is perhaps 
due to the absence of carbohydrate moieties, which may hinder their proper 
assembly, or the requirement for intact carbohydrate moieties of J chains of the 
polymeric molecules. The J chains of the polymeric immunoglobulins have been 
demonstrated to be indirectly involved in facilitating secretion (reviewed by 
Koshland, 1985). However, a recent report by Cattaneo and Neuberger (1987) has
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demonstrated that in absence of J chains, assembly and secretion of IgM can occur 
as efficiently.
1.43, Protection Against Degradation.
In certain glycoproteins, e.g., fibronectin and the acetylcholine receptor, 
the failure to detect secretion upon inhibition of glycosylation is due not to the 
inability of the non-glycosylated proteins to be exported, but rather is because they 
are being degraded intracellularly. Interference with N-glycosylation of these 
proteins has been shown to enhance their intracellular degradation (reviewed by 
Olden et al., 1982). Non-glycosylated IgM has similarly been shown to be more 
rapidly catabolized within the cell (Dulis et al., 1982). Therefore, the carbohydrate, 
in these cases, serves to protect glycoproteins against specific proteases. The exact 
mechanism involved in such protective function is still unresolved. Enhanced 
proteolysis could be due to the exposure of sensitive sites of the proteins in the 
non-glycosylated state or alternatively it could be a result of the co-packaging of 
lysosomal hydrolases with surface or secretory products during export.
While the total carbohydrate structures provide protection for sensitive 
sites on the proteins from the actions of proteases, the transfer of terminal sugars to 
oligosaccharide moieties have also been demonstrated to serve a similar purpose but 
in a slightly different context. Most glycoproteins are known to have terminal sialic 
acid residues in the oligosaccharide chains, and are thus termed the "complex type" 
(see section 1.2.2). One of the functions of this process is to prevent the inner 
sugar residues (normally galactose) from being recognized by specific receptors 
mediating pinocytosis and catabolism of glycoproteins. Asialoglycoproteins have 
been demonstrated to be efficiently internalized by hepatocytes, fibroblasts and 
macrophages through this mechanism (reviewed by Ashwell and Harford, 1982). 
Similarly, it has been shown that the enzymic removal of sialic acids from whole
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erythrocytes leads to their rapid clearance from the blood stream (Schauer, 1982). 
These erythrocytes were then detected to be bound to macrophages and were later 
phagocytosed (Schauer, 1982; Schauer et al.t 1984).
Another example of the protective roles played by carbohydrate moieties is 
the glucosylation of the lipid-linked oligosaccharide occuring in the rough 
endoplasmic reticulum. In rat splenic lymphocytes, it has been discovered that non- 
glucosylated lipid-linked oligosaccharides were selectively degraded by a 
phosphodiesterase, clearly suggesting the protective role of the glucose residues 
(Hoflack et al., 1981). In addition, Parodi and his co-workers (1983 and 1984) 
have also shown that protein-bound non-glucosylated high mannose units may be 
transiently reglucosylated by an endoplasmic reticulum glucosyltransferase. This 
reaction has been demonstrated in mammalian, avian, protozoan and plant cells but 
is not detectable in yeast (Parodi et al., 1983 and 1984). While no function for this 
reglucosylation has been demonstrated, it was speculated that the glucosylation 
served to protect protein-linked oligosaccharides from extensive degradation by the 
mannosidase of the endoplasmic reticulum.
1.4.4. Involvement in Ligand-Receptor Interactions.
As described in section 1.2.3, although all N-linked oligosaccharide 
chains of glycoproteins arise from a common biosynthetic pathway, subsequent 
modification processes have resulted in a diverse structural array of final 
oligosaccharide conformations. Carbohydrate molecules are well known for their 
high antigenicity (Feizi, 1984). Thus, the fine-structural differences could serve as 
specific ligands or receptors to meet the various specialized functions. The roles of 
these receptors could be further classified by functional criteria.
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1.4.4.1. Interactions in Transport Mechanisms.
Cell surface lectin receptors, which are themselves glycoproteins, have 
been clearly demonstrated to be involved in mediating pinocytosis (reviewed by 
Ashwell and Harford, 1982). In liver cells, where hydrolases are being actively 
taken up and waste products rapidly catabolized, receptors for specific carbohydrate 
configurations have been detected. By means of in vivo serum clearance studies 
and actions of glycosidases to obtain specific structure of the carbohydrate moieties, 
receptors for terminal galactose (Morell et al., 1968; Hickman et al., 1970), 
mannose/N-acetylglucosamine (Stahl et al., 1976; Achord et aL, 1977), fucose 
(Prieels et al., 1978) and mannose-6 -phosphate (Fischer et al., 1980) residues 
have been detected on the plasma membrane of hepatocytes. Analysis of these 
receptors have clearly indicated that they are actively involved in recognizing and 
transporting the appropriate glycoproteins into the cells. Whether they are also 
involved in directing the glycoproteins to be degraded in the lysosome remains to be 
resolved. Studies assessing the importance of the carbohydrate units of these 
receptors have led to different conclusions. While the N-linked carbohydrate 
moieties of the mannose-6 -phosphate receptors are crucial for their efficient ligand- 
binding, that of the asialoglycoprotein receptors are not quite as important (Breitfeld 
etal ,  1984).
Macromolecular internalization of low density lipoprotein (LDL), 
transferrin, epidermal growth factor (EGF) and insulin has also been reported to 
occur via the receptor-mediated endocytic mechanism (reviewed by Brown et al., 
1983, Pastan and Willingham., 1983 and Helenius et al., 1983). One common 
feature shared by the receptors for the macromolecules is the possession of re­
linked carbohydrate chains. However, this does not distinguish the receptors from 
other cell-surface proteins, such as histocompatibility antigens, that do not 
participate in endocytosis. In the case of the insulin receptor, although its
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carbohydrate units have been shown to be crucial for ligand binding and signal 
transmission processes (Reed etal., 1981; Ronnet and Lane, 1981; Cherqui etal.,
1982), their conversion to the complex-type structure is not as important (Duronio 
et al., 1986). The role of the carbohydrate moieties in regulating the functions of 
the other receptors have yet to be assessed.
The involvement of lectin receptors in mediating exocytosis or secretion of 
glycoproteins has only begun to emerge. Following the elucidation of the 
oligosaccharide processing pathway of N-linked carbohydrate chains of 
glycoproteins (see section 1.2.2), specific lectins have been suggested to facilitate 
the transport of the macromolecules and their destination-targeting processes 
(reviewed by Olden et al., 1982). Many membrane receptors that are engaged in 
pinocytosis, described in the above paragraph, have apparently been discovered to 
be more concentrated in intracellular compartments like the rough endoplasmic 
reticulum and the Golgi apparatus (Bleil and Bretscher, 1982). However, with the 
exception of mannose-6-phosphate receptors, their exact roles are still 
undetermined. The only established receptor-mediated intracellular transport 
mechanism is that of the lysosomal glycoproteins. These proteins have been shown 
to be phosphoiylated in the cis-cistemae of the Golgi stack (reviewed by Sly and 
Fischer, 1982), and their transport to the lysosomes is mediated by receptors for 
mannose-6-phosphate, shown to reside in the rough endoplasmic reticulum and the 
Golgi apparatus (reviewed by von Figura and Hasilik, 1986).
The question of whether a similar receptor-mediated exocytic mechanism 
also applies to secretory and membrane-associated glycoproteins is intriguing. 
Preliminary studies appear to indicate the existence of such a mechanism, at least 
for some glycoproteins, and at certain stages of the oligosaccharide processing. The 
various inhibitors of the asparagine-linked oligosaccharide processing (see section
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1.3.2) that are available certainly assure rapid progress in this area. Already, studies 
utilizing glucosidase inhibitors demonstrate selective inhibitory effect on 
glycoproteins (see table 2). However, interference with Golgi mannosidases 
appears not to exert any inhibitory effect on the kinetics of the glycoprotein 
transport (see table 2). The selective inhibition in these cases suggests the existence 
of rate-limiting steps and the possible involvement of a receptor-mediated 
trafficking mechanism, especially at the level of inter-compartmental transport 
between endoplasmic reticulum and Golgi apparatus. This is most appropriate in 
cases where the physiological concentrations of the glycoproteins need to be 
carefully monitored and strictly controlled. Such a mechanism may therefore be less 
relevant for cells at a differentiation stage fully committed in the secretion of 
glycoproteins (e.g., immunoglobulin secretion from plasma cells).
I.4.4.2. Interactions Mediating Biological Functions.
Carbohydrate molecules have been implicated in numerous interactions 
mediating biological functions. One of the most intriguing discoveries in assessing 
the functional role of carbohydrate constituents of glycoproteins is the identification 
of the various blood group antigens. To date, at least twenty different blood group 
systems have been recognized in man (Race and Sanger, 1975). Distinctions 
between the groups vary from a single sugar substitution at the erythrocyte surface 
carbohydrate molecules, as in the case of A and B blood group antigens, to a few 
sugar residues. Antibodies to foreign erythrocyte surface antigens are naturally 
produced.
Carbohydrate units have also acted as antigenic epitopes in numerous 
other systems. Studies utilizing monoclonal antibodies have revealed that most cell 
surface differentiation and tumour associated antigens from diverse cell types are 
indeed saccharide structures of glycoproteins and glycolipids (Thorpe and Feizi, 
1984; Feizi et al., 1984). These antigenic markers belong to a family of
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carbohydrate structures which also include the major blood group antigens.
The Major Histocompatibility Complex (MHC) encodes other surface 
antigens that mediate immunological specificity. These glycoproteins which possess 
N-linked glycans are essential for reactions of specific immune recognition. Foreign 
cells are recognized by their distinct MHC molecules and are thus acted upon by the 
cytotoxic T cells (reviewed by Burakoff et al., 1984). Recognition and lysis of 
syngeneic virally-infected cells is regulated by the MHC as well as the viral antigens 
(Zinkemagel and Doherty, 1974; Shearer, 1974). Oligosaccharide moieties of the 
MHC molecules and of the G proteins of the vesicular stomatitis virus-infected 
cells, however, have so far been found not to confer any specific immunological 
function as assessed by their non-glycosylated form reactivity with alloantisera, 
MHC-directed monoclonal antibody as well as cytolysis by alloimmune cytotoxic 
cells (Parham etal., 1977; Ploegh etal., 1981; Blacker al., 1981).
Another of the body’s defence mechanisms involved in the destruction of 
foreign elements is the activation of the enzyme cascades of the complement 
system. Generally, the complement's three major functions are; the activation of the 
immune system (e.g., macrophages), opsonization, where complement facilitates 
the phagocytosis of antigens, and cytolysis of target cells (reviewed by Perlmutter 
and Cotton, 1986 and Muller-Eberhard, 1986). One of the routes involved in the 
fixation of complement is through the binding of Clq subcomponent of the cascade 
by bound antibodies, i.e., the classical complement pathway. In IgG isotypes, Clq 
binding has been shown to occur at the Cy2 domains of the antibody molecule 
(Ellerson etal., 1972; Yasmeen etal., 1976), which are also known to contain r e ­
linked oligosaccharide chains (see figure 5). It has further been shown that binding 
of Clq subcomponent to non-glycosylated IgG is markedly impaired compared 
with that of fully-glycosylated molecules, implicating the involvement of the
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Figure 5. The basic structures of IgG and monomeric IgM molecules.
Structures of IgG and monomeric IgM molecules are schematically illustrated. The 
amino terminal end is characterized by sequence variability (V) in the heavy (H) and 
light (L) chains. The rest of the molecules have relatively constant structures. The 
constant portion of the light chain is termed the Cl region. The constant portion of 
the heavy chain is further divided into three discrete domains for IgG (i.e., Cyl, 
Oy2 and Cy3) and four domains for IgM (i.e., Cp 1, Cp2, Cp3 and Cp4). Each of 
the y-heavy chains possess one complex-type N-linked carbohydrate moiety (Asn- 
297). The p-heavy chain contains five N-linked oligosaccharide chains, of which 
three are complex-typed (Asn-170, -332 and -395) and the other two having high 
mannose structures (Asn-402 and 563) (reviewed by Winkelhake, 1978).
KEY:
Q  - hinge region
(H - complex-type N-linked oligosaccharide 
@  - high mannose-type N-linked oligosaccharide
HYPERVARIABLE
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carbohydrate units (Koide et al., 1977; Winkelhake et al., 1980; Nose and 
Wigzell, 1983). This phenomenon has been demonstrated to arise from the increase 
in the values of the binding interactions of Clq with non-N-glycosylated IgG, 
although the binding capacity is not affected (Leatherbarrow et al., 1985). 
Interestingly, the presence of free sugar molecules has also been observed to have a 
slightly inhibitory effect (Koide et al., 1977).
Analogous to the fixation of complement, immunoglobulin carbohydrate 
moieties have also been implicated to be involved in other Fc-mediated phenomena, 
i.e., direct binding with monocytes or macrophages or by rosette formation with 
sheep erythrocytes, and the induction of antibody dependent cellular cytotoxicity 
(ADCC) (Koide et al., 1977; Nose and Wigzell, 1983). Although most early 
reports on the binding interactions in these biological activities have indicated 
involvement of the Cy3 domains of IgGs (Okafor et al., 1974; Ciccimarra et al:, 
1975; Barnett-Foster et al., 1980), studies by Burton and co-workers (Woof et 
al., 1984 and 1986; Partridge et al., 1986) have conversely suggested that the 
monocyte binding domain on human IgG is found on the Gy2 domain. Thus, a 
direct involvement of carbohydrate moieties in the Fc binding interactions is still 
highly possible.
1.4.4.3. Interactions in Disease-Associated Phenomena.
Autoimmune disorders are diseases in which the body abnormally 
generates antibodies against self-antigens. This could either be a consequence of an 
external induction leading to the generation of antibodies to the self-antigens or a 
result of abnormal changes of the body's own self-antigens. In many of the 
reported autoimmune disorders, autoantibodies are demonstrated to be directed 
against carbohydrate epitopes (Parekh etal., 1985; Feizi and Childs, 1985).
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The sera of patients with the autoimmune hemolytic disorder known as 
cold agglutinin disease (which is associated either with chronic lymphoproliferative 
disorders or may transiently follow infections with Mycoplasma pneumoniae or 
Epstein Barr virus) have been reported to consist of monoclonal antibodies directed 
against the developmentally regulated carbohydrate I and i antigens of human 
erythrocytes (Feizi and Childs, 1985). The i antigen (consisting of repeating N- 
acetyllactosamine units) is a marker of human foetal erythrocytes and is largely 
substituted by the I antigen (consists of a "branched-type" repeating N- 
acetyllactosamine units) at approximately one year of age.
Rheumatoid arthritis is a well known disease in which the immune 
complexes that are present consist exclusively of immunoglobulins. The sera of 
patients suffering from this disease have been reported to consist largely of 
antibodies with transformed N-linked oligosaccharides. These antibodies could 
both act as the autoantigen (most commonly IgG) as well as the rheumatoid factor. 
Characterization of the carbohydrate moieties of IgGs from these patients 
demonstrates that they largely consist of the agalactoside-type oligosaccharide 
chains (Parekh etal., 1985). These novel carbohydrate moieties of IgGs have also 
been shown to exist in the sera of primary osteoarthritic patients (Parekh et al.t
1985).
1.5. Models of Intracellular Routing of Glycoproteins.
1.5.1. Mechanisms of Intracellular Routing.
Accumulated evidence has indicated no unifying mechanism of 
glycoprotein transport. Carbohydrate moieties of glycoproteins are involved in the 
mechanism of transport of some glycoproteins but appear to have no function in 
others (see section 1.4.2).
At least three classes of glycoproteins, i.e., plasma membrane, secretory
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and lysosomal glycoproteins use a common site, the rough endoplasmic reticulum, 
for their membrane translocation. Current evidence suggests that only in case of the 
latter, do carbohydrate moieties play a role in the regulation of transport of 
glycoproteins (see section 1.4.4.1). Studies from different systems appear to 
indicate that oligosaccharides are not crucial for the transport of secretory and 
membrane glycoproteins (see section 1.4.4.1; Greene etal., 1981). In specific 
cases, where inhibition of N-glycosylation leads to the termination of protein 
export, disruption is more likely to be due to the severe changes in the 
physicochemical properties of the proteins (Hickman and Komfeld, 1978).
The intracellular sorting of proteins is an unequivocally clear phenomena, 
as demonstrated in the epithelial cells, MDCK. Membrane proteins of these cells are 
observed to be segregated into two distinct plasma membrane domains, i.e., apical 
and basolateral, which are biochemically, physiologically and morphologically 
distinct (Misfeldt et al., 1976; Cereijido et al., 1978 and 1980; Louvard, 1980). 
Carbohydrate moieties have been shown not to be involved in the trafficking of 
these proteins (Green et al., 1981). However, the existence of the sorting 
phenomena certainly demonstrates multiple mechanisms of intracellular protein 
segregation and also implicates the involvement of a receptor-mediated transport 
process.
The common existence of two distinct transport mechanisms within a 
single cell has also been unravelled in the endocrine cell line AtT-20 (Gumbiner and 
Kelly, 1982). While most of plasma membrane glycoproteins of these cells follow 
the constitutive mechanism, export of secretory glycoproteins requires appropriate 
signals. These proteins are firstly retained in storage vesicles and only released 
when the appropriate signals are acquired. Regulation of exocytosis often involves 
the activation of G protein, although the mechanisms that are associated vary
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between distinct cell types (reviewed by Burgoyne, 1987). Transport via the 
constitutive mechanism may occur either by a distinct receptor-mediated process or 
simply by non-carrier-mediated bulk flow (Moore and Kelly, 1985).
While the transport of selective proteins clearly demonstrates involvement 
of specific signals, existing evidence appears to indicate that most of the other 
proteins that are destined for export or deposition into the plasma membrane are 
simply transported by bulk flow. Studies on the export of simple glycopeptides that 
follow normal intracellular routing via endoplasmic reticulum and Golgi apparatus 
to the cell surface have demonstrated an equal or a slightly faster rate of transport 
compared to those of the plasma membrane and secretory proteins (Wieland et al., 
1987). With the existence of such a rapid and efficient intracellular bulk flow, the 
export of proteins certainly does not require any form of receptor-mediated 
mechanism. Proteins that are free to diffuse through the membrane of the rough 
endoplasmic reticulum may be swiftly swept to the cell surface by default. Thus, 
the view that there may exist receptors that may promote the transport of proteins 
(Fitting and Kabat, 1982) is becoming more unpopular.
Another line of evidence that strongly support this notion is the 
identification of signals that act to retain specific proteins in particular intracellular 
compartments. Several reports have already described that deletion of part of 
glycoproteins that normally reside in the endoplasmic reticulum resulted in their 
transportation to the cell surface or secretion into the extracellular environment, 
suggesting that the truncated fragment may contain the specific signal for retention 
(Poruchynsky etal., 1985; Paabo etal., 1987). More direct evidence comes from 
the recent work of Munro and Pelham (1987). They have observed that a number of 
proteins found in the endoplasmic reticulum possess common tetrapeptide 
sequence, Lys-Asp-Glu-Leu. Deletion of this sequence from one of the proteins
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was subsequently demonstrated to result in its secretion. Moreover, when the 
sequence was transplanted to the C-terminus of lysozyme, which is a protein that is 
normally secreted, the lysozyme derivative was found to be retained in the 
endoplasmic reticulum.
Compartmental retention of proteins may also be accomplished by a 
slightly different mechanism. It is well known that the subunit assembly of 
immunoglobulins and histocompatibility antigens is a prerequisite for their 
secretion. Non-assembled heavy chains of immunoglobulins have been found to be 
associated with a cellular protein located in the lumen of the endoplasmic reticulum, 
known as BiP, i.e., immunoglobulin heavy chain binding protein (Haas and Wabi, 
1983; Gething etal., 1986). Immunoglobulin heavy chains are only released from 
these proteins when their proper assembly with the light chains has taken place. 
Bole et al. (1986) have accordingly suggested that BiP functions as a safeguard 
measure in the prevention of export of improperly assembled molecules. Another 
protein that may be regulated by the same mechanism is the influenza viral 
haemagglutinin (HA). Non-assembled HA molecules have also been found to be 
associated with BiP, and release of these molecules may only occur after 
completion of their trimerization process.
1.5.2. Rationale of Distinctive Mechanisms of Intracellular Routing.
The different types of intracellular trafficking mechanisms that have been 
proposed appear to be constructed to meet the functional requirements of individual 
types of glycoproteins and cells. The transport mechanism involving mannose-6 - 
phosphate ligand-receptor interactions is exclusively designed for the lysosomal 
enzymes to be routed to the lysosomes (reviewed by von Figura and Hasilik, 
1986). In the absence of carbohydrate moieties, transportation of these enzymes is 
chaotically disrupted. Involvement of such mechanisms are also observed in the 
transport of other intracellular-site-specific proteins such as those residing in the
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mitochondria (reviewed by Colman and Robinson, 1986; Hurt and van Loon,
1986), although signal sequences may not be carbohydrate residues.
In addition, signal sequences may also act to retain proteins in specific 
compartments (reviewed by Rothman, 1987). Most secretory and plasma 
membrane-associated proteins are strongly believed to be transported to the cell 
surface, en routing the rough endoplasmic reticulum and Golgi apparatus, by bulk 
flow (Wieland et al., 1987). In order to abstain from being swept by such a 
mechanism, resident proteins of the endoplasmic reticulum and Golgi apparatus 
have acquired specific retention signal sequences that embed themselves to their 
respective compartments. A slightly different retention mechanism may also exist in 
the cell to prevent the secretion of improperly assembled macromolecules. The cell 
has developed certain proteins that function to retain defective molecules from 
further transportation (Bole etal., 1986).
In the case of endocrine cells, a similar constitutive mechanism is also in 
existence to handle the trafficking of integral proteins. However, in order to 
maintain the physiological concentration of various hormones, another channel, that 
may be efficiently controlled, is also required. This is ingeniously achieved by the 
alternative regulatory mechanism of the same cell.
The physiological concentration of immunoglobulins of the body is also 
rigorously regulated. However, in this case, and conforming to the clonal selection 
hypothesis, regulation is postulated to be at the level of differentiation of plasma 
cells. Enhancement of antibody production is speculated to be associated with 
plasma cell blastogenesis. This notion is supported by the work of Tartakoff and 
Vassalli (1977 and 1978) who have indirectly shown that the export of 
immunoglobulins from actively secreting plasma cells occurs constitutively, without
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involvement of any regulatory mechanism.
1.5.3. Immunoglobulins as a Model System for Studying Carbohydrate Moieties
of Glycoproteins.
Immunoglobulins offer an excellent model system to study the role of N-
linked oligosaccharides of glycoproteins. Advantages of using immunoglobulins
are;
a) the availability of well established cell lines and hybridomas which secrete 
homogeneous immunoglobulins of specific isotypes and at specific 
differentiation stages;
b) the availability of specific anti-immunoglobulin antisera of high avidity, 
thus permitting easy isolation and detection of radiolabeled 
immunoglobulins;
c) the variations in types and numbers of oligosaccharide components within 
particular immunoglobulin isotypes provide a wide range of distinctive 
examples;
d) the potential role of oligosaccharides in many effector functions of 
immunoglobulins that warrants further resolution; and
e) the existence of numerous well established assays of immunoglobulins for 
low-level quantitation purposes.
1.6. Objectives of study.
The functions of carbohydrate moieties of glycoproteins are surrounded 
by much controversy. Their role in the regulation of glycoprotein transport is 
obscured by the finding that only certain glycoproteins have their secretion impaired 
under non-N-glycosylated condition (see section 1.4.1).
Many of the studies which have addressed the function of oligosaccharide 
side chains in the transport of glycoproteins have employed tunicamycin as the 
inhibitor of N-glycosylation (see section 1.3.1.2). One particular criticism of the 
data obtained from experiments using this inhibitor is that the drug itself may act to 
disrupt cellular transport processes in addition to its inhibition of protein 
glycosylation. To address this particular point, a study of the biological activities of 
three structurally-modified tunicamycin analogues with respect to macromolecular 
biosynthesis, glycosylation and immunoglobulin export from rat hybridoma cells 
was undertaken (this thesis, and Hashim and Cushley, 1987a).
The recent advent of N-linked oligosaccharide processing inhibitors 
provides a means to investigate the role of carbohydrate processing in the regulation 
of glycoprotein transport. Already, studies in many systems have indicated a similar 
selective inhibition of transport of glycoproteins (see section 1.4.2). To provide a 
wider perspective to this area of endeavour, a study was carried out to determine the 
effects of N-linked oligosaccharide processing inhibition on the transport of IgM 
and IgG2b from rat hybridoma cells (this thesis, and Hashim and Cushley, 1987b 
and c).
N-linked oligosaccharide moieties of immunoglobulins have been strongly 
implicated to be involved in various effector functions of immunoglobulins. Non- 
N-glycosylated IgGs have been reported to be less effective in activating the
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complement cascade, in direct binding with monocytes or macrophages or by 
rosette formation with sheep erythrocytes, and the induction of antibody dependent 
cellular cytotoxicity (see section 1.4.4.2). To extend these observation(s), a study 
examining the effects of IgG2b synthesized in the presence of processing inhibitors 
on the expression of effector functions of immunoglobulins was undertaken.
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CHAPTER II 
MATERIALS AND METHODS
2.1. General Materials.
The materials used during the course of this study and their respective 
suppliers are described;
2.1.1. Cell Culture Materials.
RPMI-1640 medium, foetal calf serum (FCS) and penicillin/streptomycin 
solution were obtained either from Gibco Biocult Ltd., Paisley, Scotland or 
Northumbria Biologicals Ltd., Northumbria, England. Tissue culture flasks were 
purchased from Costar Northumbria Biologicals Ltd., Northumbria, England and 
accessory sterile plastics were supplied by Sterilin Ltd., Feltham, England.
2.1.2. Fine Chemicals.
All chemicals used were of the highest grade available commercially. With 
exceptions of the following, all other chemicals were supplied by BDH Chemicals, 
Poole, Dorset, U.K.
Tris (hydroxymethyl) aminomethane (i.e., trizma base) was obtained from 
Boehringer Corporation, Lewes, U.K.
Hydrogen peroxide and sodium hydrogen carbonate were purchased from 
Fisons Scientific Apparatus Ltd., Loughborough, Leics., U.K.
Sodium chloride and sucrose were supplied by Formachem Ltd., 
Strathaven, Scotland, U.K.
Calcium chloride, calcium nitrate tetrahydrate and sodium hydroxide were 
obtained from Hopkins and Williams, Chadwell Heath, Essex, U.K.
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Dimethylsulphoxide and trichloroacetic acid were purchased from Koch 
Light Laboratories, England.
Amino acids, D-galactose, D-mannose, methyl-a-D-glucopyranoside, 
methyl-a-D-mannopyranoside, N-acetylglucosamine, O-phenylene diamine, 
salicylic acid, sodium deoxycholate, sodium pyruvate, and vitamins were supplied 
by Sigma Chemical Co. Ltd., Poole, Dorset, England.
2.1.3. Tunicamycin and Analogues.
Tunicamycin was purchased either from Sigma Chemical Co. Ltd., Poole, 
Dorset, England, Boehringer Corporation, London, England or Miles Laboratories 
Ltd., Slough, U.K. Analogues of tunicamycin were kindly provided by Drs. R.T. 
Hotstons and A.R. Williamson of Glaxo Group Research Ltd.
2.1.4. Inhibitors of Oligosaccharide Processing.
Castanospermine (CSP), 1-deoxynojirimycin (dNM), 1-deoxymanno- 
jirimycin (dMM) and Swainsonine (SW) were obtained from Boehringer 
Corporation, Lewes, U.K.
2.1.5. Radiochemicals.
All radiochemicals were obtained from the Amersham International pic., 
Amersham, England. The specific activities of the radiochemicals used are 
described in table 5.
2.1.6. Enzymes.
All enzymes were purchased from Boehringer Corporation, Lewes, U.K. 
The specific activities of the enzymes are described in table 6 .
4 5
Table 5. Specific activities of radiochemicals.
Radiochemicals Specific Activities
L- [3 5S] -methionine >1200Ci/mmol
L- [4,5-3H]-leucine 53Ci/mmol
[methyl-3H]-thymidine 52Ci/mmol
[5-3H]-uridine 28.5Ci/mmol
D-[2-3H]-mannose 19Ci/mmol
Table 6. Specific activities of enzymes.
Enzymes Specific Activities
Endoglycosidase H (S. plicatus) 45I.U./mg
Glycopeptidase F (F. meningosepticum) 25,000U/mg
Neuraminidase (C. perfringens) 3U/mg
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2.1.7. Serological Reagents.
Rabbit anti-rat IgG (RArlg)
Donkey anti-rabbit IgG (DARIg) 
Guinea pig complement 
Haemolysin
RArlg-Horseradish-peroxidase
Miles Laboratories Ltd., Slough, 
U.K.
Scottish Antibody Production Unit. 
Sera-Lab, Sussex, U.K.
Flow Laboratories Ltd., Irvine, 
Scotland.
Miles Laboratories Ltd., Slough, 
U.K.
2.1.8. Electrophoretic Materials.
Acrylamide, 2-mercaptoethanol, N,N'-methylene bis acrylamide, 
N,N,N'N'-tetramethylenediamine (TEMED) and ammonium persulphate were 
obtained from BDH Chemicals, Poole, Dorset, U.K.
2.1.9. Photographic Materials.
X-Omat-H X-ray film Kodak (U.K.) Ltd., London.
SX-80 developer Kodak (U.K.) Ltd., London.
FX-40 X-ray liquid fixer Kodak (U.K.) Ltd., London.
2.1.10. Miscellaneous Reagents.
Vibrio cholerae serotype Inaba (3S A3) was obtained from The David 
Bruce Laboratories, Wiltshire, U.K. Lipopolysaccharide (E. Coli 012.B8) and 
Concanavalin A-sepharose 4b were purchased from Sigma Chemical Ltd., Poole, 
Dorset, England. Fresh sheep erythrocytes were supplied weekly by Gibco Biocult. 
Ltd., Paisley, Scotland.
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2.2. Standard Solutions.
Unless otherwise stated, all buffers were stored at 4°C.
2.2.1. Phosphate-Buffered Saline (PBS-A).
170mM NaCl
3.4mM KC1 
10mMNa2 HPO4
1.8mMKH2P04  pH 7.2
2.2.2. TKM Buffer.
5mMMgC12 
0.1M KC1
O.IMTris-HCl pH 8.2
2.2.3. Three-Detergent Lysis Buffer (3D-TKM).
The following detergents were added to TKM buffer, 
1% (W/V) Triton X-100 
1% (W/V) Deoxycholic acid 
0.5% (W/V) SDS
2.2.4. Immunopredpitate Wash Buffer.
1% (W/V) SDS
0.01% (W/V) Phenol red
50mM Tris-HCl pH 8 .8
(Stored at room temperature)
2.2.5. SDS-PAGE Reducing Sample Buffer.
2% (W/V) SDS
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10% (W/V) Glycerol 
0.001% (W/V) Bromophenol blue 
5% (V/V) 2-mercaptoethanol 
62.5mM Tris-HCl pH 6 .8
(Stored at -20°C)
2.2.6. Con A buffer.
ImM CaCl2  
ImM MgCl2  
ImM MnCl2  
0.3M NaCl 
0.02% SDS
lOmM Tris-HCl pH 7.5
2.2.7. Glycopeptidase F Buffer.
1 % (v/v) 2 -mercaptoethanol 
0.2% (W/V) SDS 
1% (W/V) Triton-X 100 
lOmMEDTA
50mM Potassium phosphate buffer pH7.2
2.2.8. McDvaines Buffer.
Stock solutions;
A) 0.1M Citric acid
B) 0.2M Na2HP04 12H20.
Working diluent;
17.9ml of A and 32.1ml of B were mixed and the volume made up to 
100ml to give a solution of pH 6.0.
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2.2.9. Complement Fixation Assay (CFA) Buffer.
Stock solutions (10 x);
81.6g NaCl (1.4M)
12.1g Tris (0.1M)
33ml of 0.15M MgS04  
15ml of 0 .1  M CaCl2
The pH was adjusted with HC1 to 7.4 and the final volume was made up
to 1 litre.
Working diluent;
lg of BSA was dissolved in 100ml of stock solution and the final volume 
was made up to 1 litre.
2.3. Tissue Culture.
2.3.1. Rat Hybridoma Cell Lines.
Rat hybridoma 4A3 and IIA 1.4 cell lines synthesize and secrete IgM and 
IgG2b» respectively (Damato et aL, 1986; Ghosh and Campbell, 1986). Both cell 
lines were generated in this department and were kindly provided by Dr. A.M. 
Campbell.
2.3.2. Tissue Culture Medium.
The composition of RPMI-1640 medium is described in table 7. For 
"complete" tissue culture medium, the RPMI-1640 was supplemented with 10%
(V/V) foetal calf serum, 2mM fresh L-glutamine, penicillin (105 1.U./litre) and
streptomycin (lOOmg/litre). Foetal calf serum was heat inactivated at 56°C for 30 
minutes and stored at -20°C, prior to use. L-glutamine and penicillin /streptomycin 
solutions were kept at -20°C as 100 X stock.
2.3.3. Routine Culture.
Rat hybridoma 4A3 and IIA 1.4 cells were maintained in complete
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Table 7. Composition of RPMI-1640 medium.
Amino acids mgflitre Amino adds mg/litre
L-Arginine 2 0 0 . 0 L-Lysine HC1 40.0
L-Asparagine 65.0 L-Methionine 15.0
L-Aspartic acid 2 0 . 0 L-Phenylalanine 15.0
L-Cystine (2HC1) 65.0 L-Proline (hydroxy-L-
L-Glutamic acid 2 0 .0 proline free 2 0 . 0
Glycine 1 0 .0 L-Serine 30.0
L-Histidine (free base) 15.0 L-Threonine (alio free) 2 0 . 0
L-hydroxyproline 2 0 .0 L-Tryptophan 5.0
L-Isoleucine (alio free) 50.0 L-Tyrosine 15.0
L-leucine (methionine free) 50.0 L-Valine 2 0 .0
Vitamins Inorganic salts
Biotin 0 .2 Ca(N03)2 .4H20 1 0 0 .0
D-calcium pantothenate 0.25 KC1 400.0
Choline chloride 3.0 MgS04 48.84
Folic acid 1 .0 NaCl 6000.0
i-Inositol 35.0 Na2HP04 800.0
Nicotinamide 1 .0 NaHC03 2 0 0 0 . 0
para-Aminobenzoic acid 1 .0 Other components
Pyrodoxine hydrochloride 1 .0 Glucose 2 0 0 0 . 0
Riboflavin 0 .2 Phenol red 5.0
Thiamine hydrochloride 1 .0 Reduced Glutathione 1 .0
Vitamin B12 0.005
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medium in Costar flasks at 37°C in a 95% 0 2 :5 % CO2  humid incubator, and 
subcultured when confluent. Routine cell culture was performed under sterile 
conditions in a Laminar-flow hood.
2.3.4. Storage and Recovery of Cells.
Log-phase cells were harvested, washed and resuspended at 2 x 106 cells 
per ml of storage medium (i.e., RPMI-1640 supplemented with 20% (V/V) foetal 
calf serum and 10% (W/V) DMSO). 1ml of cell suspension was aliquoted into 
ciyostat ampoules (1.5ml capacity). Ampoules were kept at -70°C overnight before 
being transferred into a gas-phase liquid nitrogen freezer. For recovery, cells were 
quickly thawed at 37°C, washed twice with incomplete medium, resuspended in 
complete RPMI medium (20% foetal calf serum) and incubated at 37°C in a 
humidified incubator. The percentage of foetal calf serum was subsequently 
reduced to 1 0 % over several subcultures.
2.3.5. Determination of Cell Viability.
Trypan blue solution was prepared by mixing 1 part of 1% (W/V) trypan 
blue with 4 parts of 1% (W/V) NaCl. Cell viability was determined by mixing equal 
volumes of cell suspension and the tiypan blue solution. Numbers of live and dead 
cells were estimated by counting in a Neubauer haemocytometer.
2.4. Radiolabelling Procedures.
2.4.1. Analysis of Macromolecular Synthesis.
Cells were washed twice with serum-free RPMI-1640 medium and 
resuspended at 2.5 X 10  ^ cells/ml. lOOpl aliquots of the cell suspension were 
dispensed into individual wells of microtitre trays containing appropriate 
concentrations of tunicamycin or analogues. After 3 hours at 37°C, each well was 
pulsed with l.OpCi/well of radioactive macromolecular precursor and further
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incubated for 1 hour at 37°C. Samples were then automatically harvested using a 
Skatron cell harvester. Radioactivity was determined by liquid scintillation 
spectrometry (section 2.5.7).
2.4.2. Pre-Treatment of Cells.
Prior to labelling, 2.5 x lev iab le  cells were harvested from log-phase 
cultures and exposed to the appropriate drugs. In case of tunicamycin and its 
analogues, cells were subjected to three hours exposure at 2 pg/ml in order to 
exhaust the pre-existing glycosylated products within the cell. Treatment with the 
processing inhibitors, however, involved a one hour pre-exposure. The final 
concentrations of the processing inhibitors used were as follows;
Castanospermine 75ug/ml
1-deoxynojirimycin 5mM
1-deoxymannojirimycin ImM
Swainsonine lOug/ml
These processing inhibitors were dispensed from 100 X stock solutions that were 
stored at 4°C. Control samples were treated similarly but in absence of any drugs.
2.4.3. Biosynthetic Labelling.
After treatment with the various inhibitors (section 2.4.2), cells were 
washed twice with serum-free RPMI-1640 lacking methionine (i.e., labelling 
medium). The cells were resuspended in 200pl of the labelling medium 
supplemented with lOOjiCi 3 5S-methionine and incubated at 37°C for 60 minutes. 
For mannose labelling, cells were washed with and resuspended in RPMI-1640 
medium containing sodium pyruvate as energy source instead of glucose. Tritiated 
mannose was normally obtained in 50% (V/V) ethanol solution and therefore had to 
be lyophilized and resuspended in labelling medium, prior to use. 50-75pCi of 
tritiated mannose were normally used for each labelling and incubation was carried
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out for 90 minutes. In case of drug-treated cells, the washing and labelling medium 
also contained the appropriate concentrations of the drugs.
2.4.4. Pulse-Chase Experiments.
Cells were biosynthetically radiolabeled as described in section 2.4.3. 
After the labelling period, cells were pelleted and resuspended in 500jil of complete 
RPMI-1640. Aliquots of 125gl were immediately collected upon resuspension; the 
cells were pelleted and subjected to lysate preparation (section 2.5.1). The 
remainder of cell suspensions were reincubated at 37°C for further 4-6 hours. At 
the appropriate chase intervals (see individual figures), 125pl aliquots of cell 
suspensions were collected. Cells were pelleted and the culture supernatants were 
collected and prepared for immunoprecipitation as described in section 2.5.2.
2.5. Analysis of Cellular Proteins.
2.5.1. Preparation of Lysates.
Cell lysates were prepared in the three-detergent buffer system described 
by Mosmann et al. (1978 and 1979). Radiolabeled cells were washed twice with 
ice-cold TKM buffer (section 2.2.2), resuspended in 8  volumes of the same buffer 
and lysed by addition of 1 volume of 10% (W/V) triton X-100 in TKM buffer. The 
suspension was allowed to stand on ice for 20 minutes. Nuclei were removed by 
centrifugation (3,000 X g for 30 minutes) and the resulting supernatant was added 
to 1 volume of 10% (W/V) deoxycholate/5% (W/V) SDS in TKM buffer. Insoluble 
debris was removed by high speed centrifugation (30,000 X g for 30 minutes) and 
the supernatant was either used immediately for serological analysis or stored at -70 
°C. If stored, the high speed centrifugation step was repeated on the thawed lysate.
2.5.2. Preparation of Culture Supernatants.
Prior to immunoprecipitation, culture supernatants, following the 
appropriate chase periods, were obtained by pelleting the cells (500 X g) and
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subjecting the cell supernatant to high speed centrifugation (30,000 X g for 30 
minutes).
2.5.3. Total Protein Precipitation.
Determination of total cellular proteins was done by acid-precipitating 
radiolabeled lysates on glass fibre discs. Aliquots of cell lysates were dispensed 
onto glass fibre discs, air-dried and immersed into two successive baths of 1 0 % 
(W/V) ice-cold trichloroacetic acid for 60 minutes. Discs were rinsed with absolute 
alcohol, air-dried and counted by liquid scintillation spectrometry (section 2.5.7).
2.5.4. Serological Titration of RArlg and DARIg.
To determine the optimal volumes of RArlg and DARIg, prior to usage in 
indirect immunoprecipitation procedures (section 2.5.5), a titration of the two 
antibodies was performed. Different volumes of DARIg were added to lOpl of 
RArlg (1:10 dilution) and the solution was made up to 250pl with PBS. Mixtures 
were incubated at room temperature for 1 hour and overnight at 4°C. Precipitates 
were collected by centrifugation, washed four times with PBS and resuspended in 
lml of 0.1 M sodium hydroxide. Absorbance was measured spectrophotometrically 
at 280nm. Figure 7 demonstrates the titration profile of the two antibodies. The 
optimal serological titration of the two antibodies was represented by the mixtures 
exhibiting the maximum absorbance reading, i.e., 40jil DARIg to lpl RArlg.
2.5.5. Indirect Immunoprecipitation.
lOpl of 1:10 dilution of RArlg was added to an aliquot of cell lysate or 
culture supernatant and incubated at room temperature for 30 minutes. A serological 
equivalence of DARIg, as determined in section 2.5.4, was added and the mixture 
was incubated overnight at 4°C. Immunoprecipitates were harvested by 
centrifugation.
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Figure 6. Serological titration of DARIg and RArlg.
Determination of the optimal serological titre of DARIg and RArlg is described in 
section 2.5.4. Mixtures of lOpl (1:10 dilution) of RArlg and different 
concentrations of DARIg were incubated at room temperature for one hour and 
overnight at 4°C. Absorbance of the precipitates was measured 
spectrophotometrically at 280nm. Each point represents mean absorbance values of 
duplicate samples. Bars indicate standard deviation. The optimal serological titration 
of the two antibodies are represented by the mixtures exhibiting the maximum 
absorbance reading, as indicated by arrow (i.e., 40jil DARIg to ljil RArlg).
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2.5.6. Purification of Serological Precipitates.
Harvested immunoprecipitates from section 2.5.5 were resuspended in 
lOOjil 3D-TKM buffer and layered onto the top of two-step discontinuous sucrose 
gradient. The gradient consisted of 300p.l of 1M sucrose in 3D-TKM and 300pl of 
0.5M sucrose in 3D-TKM. After addition of sample, the gradients were centrifuged 
at 3,000 X g for 30 minutes and rinsed with immunoprecipitate wash buffer (section 
2.2.4) without disturbing the precipitates. The washed immunoprecipitate was 
either dissolved in SDS-PAGE reducing sample buffer or stored in 3D-TKM buffer 
at 4oC.
2.5.7. Liquid Scintillation Counting.
Samples were added to scintillation vials containing 3ml of ecoscint and 
counted in a Beckman LS Liquid Scintillation Spectrometer.
2.6. Enzyme Analysis.
2.6.1. Endo H Digestion.
Washed immunoprecipitates were precipitated three times with 5 volumes 
of acetone and resuspended in 50mM citrate buffer (pH 5.5) containing 0.01% 
SDS. After the final wash, the precipitates were suspended in 50pl of the citrate 
buffer, boiled and 5mU of endo H were added (the enzyme was stored in aliquots 
of 5mU/20pl citrate buffer at -70°C). Digestion was allowed to proceed at 37°C for 
18 hours. Mock-treated samples were treated under the same buffer conditions in 
absence of enzyme. Reactions were terminated by addition of concentrated reducing 
sample buffer and boiling for 5 minutes (Tarentino et al.y 1978).
2.6.2. Glycopeptidase F Digestion.
Digestion of immunoprecipitates with Glycopeptidase F was performed as 
in section 2.6.1 using Glycopeptidase F buffer pH 7.2. Samples were treated with
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1U of the enzyme (Plummer et al., 1984).
2.6.3. Neuraminidase Digestion.
Prior to enzyme digestion, immunoprecipitates were acetone precipitated 
as in section 2.6.1 and resuspended in 50mM sodium acetate buffer (pH 5). 
300mU of neuraminidase was then added to the samples. Digestion was allowed to 
proceed at 37°C for 18 hours. Control samples were treated under the same buffer 
conditions in absence of enzyme. Reactions were terminated as in section 2.6.1.
2.6.4. Pronase Digestion.
Digestion of immunoprecipitates with Pronase was performed as in 
section 2.6.1 using 25mM Ammonium bicarbonate solution. Samples were treated 
with a final concentration of 0 .1  mg/ml of the enzyme.
2.6.5. Concanavalin A-Sepharose Chromatography.
Tritiated-mannose labelled IgG2b were immunoprecipitated as described in 
section 2.5.5. Immunoprecipitates were treated with various enzymes (see 
individual figure legend). Reaction was stopped by boiling. Samples were diluted 
with Con A buffer (section 2.2.6) and loaded on to a Con A column (200pl bed 
volume) equilibrated with the same buffer. This is followed by elution with 1.5ml 
of Con A buffer, lOmM methyl-a-D-glucopyranoside and lOOmM methyl-a-D- 
mannopyranoside, respectively. Radioactivity of the elutions as well as the Con A- 
sepharose beads was determined. Results are expressed in percentage of 
radioactivity.
2.7. Polyacrylamide Gel Electrophoresis.
SDS-polyacrylamide gel electrophoresis was performed according to the 
discontinuous buffering system of Laemmli (1970).
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2.7.1. Stock Solutions.
Unless otherwise stated all solutions were stored at 4°C.
Solution A.
45% (W/V) Acrylamide
1.2% (W/V) N,N'-methylene bis aciylamide
Solution was deionized with amberlite MB-1,filtered and stored in a dark
bottle.
Solution B.
1.5M tris-HCl (pH 8 .8 )
0.13% (V/V) TEMED 
Solution C.
12% (W/V) SDS.
solution was kept at room temperature.
Solution D.
10% (W/V) Ammonium persulphate.
Solution E.
0.65M Tris-HCl (pH 6 .8 )
Reservoir Buffer (5 
125mM Trizma base 
660mM Glycine 
1% (W/V) SDS
Solution was kept at room temperature.
2.7.2. Separating Gel Preparation.
Separating gels (10% acrylamide) were prepared from stock solutions as
follows;
Solution A (ml) 
Solution B (ml)
13.3
15.0
Solution C (ml) 0.5
Solution D (ml) 0.5
Deionized water (ml) 30.7
The solution was immediately poured into casting apparatus and allowed 
to polymerize.
2.7.3. Stacking Gd Preparation.
Stacking gels were prepared from stock solutions as follows;
Solution A 2.64ml
Solution C 0 .2 0 ml
Solution D 0 .2 0 ml
Solution E 2.40ml
Deionized water 18.32ml
TEMED 24pl
The solution was poured onto the top of the separating gel and allowed to
polymerize around a 2 0  well teflon template.
2.7.4. Sample Preparation and Electrophoresis.
Immunoprecipitates were dissolved in 20-25pl of reducing sample buffer 
(section 2.2.5) and heated to 100°C for 2 minutes. Samples were immediately 
loaded into individual wells in the stacking gel. Electrophoresis was performed 
either for 4-5 hours at a constant current of 45mA or 18-20 hours at 10mA.
2.7.5. Fluorography.
Fluorography was performed according to Chamberlain (1979). Gels 
were immersed into two successive baths of 1M sodium salicylate for one hour. 
The gels were then dried onto a Whatman 3mm chromatography paper under 
vacuum at 80°C and exposed to X-ray films at -70°C.
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2.7.6. Development of Films.
After exposure, fluorographic images were visualized by immersing the 
film in DX-80 developer for 5 minutes, rinsing with water and then immersing in 
FX-40 fixer for 2 minutes. The film was rinsed with water and allowed to air-dry 
prior to inspection. All operations were done in the dark room using filtered lighting 
facilities.
2.8. Immunoglobulin Assays.
2.8.1. Treatment with Inhibitors.
2 X 106  IIA 1.4 cells were pre-treated with the various inhibitors as 
described in section 2.4.2. Cells were then washed twice and resuspended in 2ml 
of complete RPMI-1640 medium containing the appropriate concentrations of 
inhibitors. Suspensions were then incubated at 37°C for 4 hours in a humidified 
incubator. Cells were then pelleted and the supernatant collected and screened by 
ELISA (section 2.8.2). Samples were then subjected to the respective functional 
assays (sections 2.8.3 - 2.8.6).
2.8.2. Enzyme-Linked Immuno Sorbent Assay (ELISA).
ELISA was performed according to Ghosh and Campbell (1986). 96-well 
microtitre plates (Dynatech MicroElisa Systems) were washed with distilled water 
and coated with 106 Inaba vibrios/1 OOpl/well in PBS. Plates were centrifuged at 
800 X g for 5 minutes at room temperature. Supernatant was removed by flicking 
the plates which were then washed twice with PBS. Plates were then blocked with 
0.5% (W/V) gelatin in PBS for 30 minutes to saturate the unreacted sites in the 
wells. Serial dilutions of samples containing antibodies were added to the plates, 
which were then incubated at room temperature for 2 hours. Plates were washed 7 
times with PBS before addition of lOOpl of RArlg covalently linked to horseradish 
peroxidase (1:1000 dilution of conjugated antibody in PBS containing 0.9% (W/V) 
NaCl and 5% (W/V) BSA) to each well. Plates were left at room temperature for
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another hour and subsequently washed 3 times with PBS. 100|xl of substrate 
solution (0.4mg/ml O-phenylene diamine with 0.01% (V/V) fresh hydrogen 
peroxide in Mcllvaines buffer) was added to each well and the plates were 
incubated in the dark for 15-20 minutes. Reaction was terminated by addition of 
50pl of 4N H2 SO4  to each well and the colour was measured at 492nm in a Titretek 
Multiskan Spectrophotometer.
2.8.3. Sensitization of Sheep Erythrocytes.
500pl of fresh sheep erythrocytes were washed with CFA working diluent 
until a clear solution was obtained. The packed sheep erythrocytes were then 
resuspended in 10ml of CFA working diluent, to which lOjil of haemolysin was 
also added. Suspension was incubated at 37°C for 30 minutes. The freshly 
sensitized sheep erythrocytes were then used for assay of complement fixation 
(section 2.8.4).
2.8.4. Complement Fixation Assay (CFA).
CFA was performed according to Wasserman and Levine (1961). lOOpl attenuated 
Inaba vibrios (107 vibrios/lOOpl) and 600pl guinea pig complement (1:400 dilution 
in CFA working diluent) were added to tubes with serial dilutions of antibody (in 
duplicate). A panel of control tubes (in absence of antibody, antigen and 
complement, respectively) and tubes solely consisting of complement solution (i.e., 
"complete lysis tubes") were also prepared. All preparations were assembled on an 
ice bath. Mixtures were incubated at 4°C overnight whereupon 200pl of 
haemolysin-sensitized sheep erythrocytes (section 2.8.3) were added to the 
individual tubes. Tubes were immediately and simultaneously incubated at 37°C 
with gradual shaking. Incubation was performed until complete lysis of sheep 
erythrocytes was observed from the "complete lysis tubes". Tubes were 
simultaneously centrifuged (3,000 X g) at 4°C for 5 minutes and supernatants were
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then measured for absorbance readings at 492nm using the Beckman 
Spectrophotometer. Percentage of complement fixation are expressed as follows;
A4 9 2  of "complete lysis" - A4 9 2  of samples
______________________________  X 100%
A492 of "complete lysis"
2.8.5. Coating of LPS on Sheep Erythrocytes.
lml of fresh sheep erythrocytes was washed with PBS until a clear 
solution was obtained. 500pl of the packed sheep erythrocytes were then added to 
lml of LPS solution (1 mg/ml) and incubated at 37°C for 60 minutes. The cell 
suspension was then washed twice with PBS, resuspended at 2 X 106 cells/ml and 
used as soon as possible.
2.8.6. Haemagglutination.
50pl of antibody samples at various dilutions were plated (in duplicate) 
into the wells of Dynatech microtitre plates. This was followed by the addition of 
50pl of LPS-coated sheep erythrocytes (section 2.8.5) into each well. Plates were 
left at room temperature overnight prior to inspection for agglutination.
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CHAPTER III 
RESULTS AND DISCUSSION
SECTION 3.1.
CHARACTERIZATION OF ANALOGUES OF TUNIC AMYCIN.
6 4
3.1.1. Model Systems.
In the course of this study, two rat hybridoma lines secreting IgM and 
IgG2 b were usec* as m°del systems. These rat lines were generated in this 
department and were kindly provided by Dr. A.M. Campbell.
Rat hybridoma 4A3 cell line was generated by fusion of spleen cells of 
DA rats immunized with human uveal melanoma cells, with the Y3 Ag 1.2.3 rat 
myeloma line (Damato et al., 1986). Isotypic determination of the 
immunoglobulins synthesized and secreted by 4A3 cells demonstrates that they are 
of the IgM class.
Rat hybridoma IIA 1.4 cell line was generated by fusion of spleen cells of 
DA rats immunized with 35A3 (Inaba) strain of Vibrio cholerae, with the Y3 Ag 
1.2.3 rat myeloma line (Ghosh and Campbell, 1986). IIA 1.4 cells synthesize and 
secrete anti-cholerae antigens of the IgG2b isotype. Characterization studies of this 
cell line by several different immunological assays has demonstrated that the IgG2b 
molecules that are secreted, although exhibit preference to the Inaba antigen, could 
also react with the Ogawa antigen of the Vibrio cholerae (Ghosh and Campbell, 
1986).
3.1.2. Analogues of Tunicamydn.
The structures of the three analogues of tunicamycin characterized in this 
study are illustrated in figure 7. The analogues are referred to as tunicamycin-1, -2 
and -3. Tunicamycin-1 has an open ring structure at the site of the uracil base and a 
saturated aliphatic side chain. The fatty acid side chain of tunicamycin-2 is similarly 
modified, but the integrity of the uracil ring is preserved. In this case, however, the 
furanose sugar group to which the pyrimidine is bound is substituted by a pyranose 
ring. Analogue tunicamycin-3 is modified by methylation of the nitrogen residue in
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Figure 7. Structures of tunicamycin and its analogues.
The structure of normal tunicamycin is shown in panel a. The analogues are; panel 
b: tunicamycin-1; panel c: tunicamycin-2; panel d: tunicamycin-3.
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the uracil moiety.
3.1.3. Macromolecular Biosynthesis.
For analysis of macromolecular synthesis, log-phase 4A3 cells were 
incubated with the indicated concentrations of the drugs for three hours prior to a 
one hour pulse with the appropriate radioactive precursor. Cells were then 
automatically harvested onto glass fibre discs, and incorporation of radioactivity 
was determined.
Figure 8  illustrates the effects of tunicamycin and analogues upon cellular 
macromolecular biosynthesis. Only normal, unmodified tunicamycin had any 
inhibitory effect upon DNA synthesis in 4A3 cells, and the extent of the inhibition 
was apparently dose-dependent (figure 8 , panel a). None of the tunicamycin 
analogues had any inhibitory effect at the concentrations tested, but all appeared to 
have a slightly mitogenic effect upon the cells.
By contrast, RNA synthesis, as assessed by tritiated uridine 
incorporation, was inhibited by all forms of the antibiotic, particularly at the highest 
concentration tested (figure 8 , panel b). This is expected since uridine components 
are present in the structures of all of the drugs and are likely to provide active 
competition for the radiolabeled precursor. As observed in the analysis of DNA 
synthesis, normal tunicamycin caused the greatest inhibition of RNA synthesis.
Protein synthesis in treated 4A3 cells was inhibited to the greatest extent 
by normal tunicamycin, and to a small but significant degree by tunicamycin-3 
(figure 8 , panel c). Neither of the tunicamycin-1 or tunicamycin-2 analogues had 
any pronounced inhibitory effect upon cellular protein synthesis. Cellular 
cytotoxicity caused in the presence of tunicamycin has been frequently observed in
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Figure 8. Effects of tunicamycin and analogues upon cellular macromolecular 
biosynthesis.
4A3 cells were incubated at 37°C for 3 hours in the presence of tunicamycin or 
analogues prior to a 1 hour pulse with appropriate tritiated macromolecular 
precursor. Panel a illustrates the data for thymidine incorporation, panel b uridine 
incorporation, and panel c refers to tritiated leucine incorporation. The open bar in 
each case represents control, untreated cells. The concentrations of tunicamycin or 
analogues were: stippled bar, lpg/ml; hatched bar, 2pg/ml; closed bar, 4pg/ml.
a)
.v.v
w.v
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several systems (see section 1.3.1.2). The question that is often raised is whether 
this inhibitory effect is a direct drug-induced response or a secondary effect due to 
interference of the drug on other cellular reactions.
The above data confirm the hypothesis that tunicamycin does inhibit 
general cellular macromolecular synthesis, but that none of the analogues tested 
exhibit pronounced toxic effects. Since the analogues, although possessing close 
structural homologies to normal tunicamycin, have not mimicked the antibiotic with 
respect to inhibitory effects upon general macromolecular synthesis, it is therefore 
reasonable to deduce that the cellular toxicity demonstrated in the presence of 
tunicamycin is a secondary effect due to the action of the drug on other cellular 
functions.
3.1.4. Quantitative Glycosylation.
4A3 cells were labelled with tritiated mannose and the level of 
incorporation into acid-precipitable glycoprotein and into immunoprecipitable IgM 
was assessed. Figure 9, panel a, illustrates that none of the tunicamycin analogues 
inhibited the incorporation of tritiated sugar into acid-precipitable glycoprotein; 
normal tunicamycin virtually abolished mannose incorporation. These data strongly 
suggest that the tunicamycin analogues are unable to inhibit the activity of the UDP- 
GlcNAc:dolichyl phosphate GlcNAc-1-phosphate transferase and, hence, protein 
glycosylation.
The data for incorporation of mannose into IgM are entirely consistent 
with those obtained for total acid-precipitable material. That is, that the tunicamycin 
analogues have no inhibitory effect upon tritiated mannose incorporation into IgM 
molecules, and that normal tunicamycin completely inhibits this process. This, 
therefore, leads to the conclusion that only native tunicamycin is capable of 
inhibiting the N-glycosylation of proteins. Further support of this notion is
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Figure 9. Effects of tunicamycin and analogues upon tritiated mannose 
incorporation.
Panel a; 4A3 cells were pre-incubated with 2jig/ml tunicamycin or analogues for 3 
hours prior to a 90 minutes pulse with 25pCi of tritiated mannose. Lysates were 
prepared in a final volume of 125jil, and immunoprecipitates were prepared from 
lOOpl aliquots of lysate. Washed immunoprecipitates were resuspended in lOOjil 
lysis buffer. 5jil aliquots of total lysate or washed immunoprecipitate were used for 
assay of radioactivity. All determinations were performed in triplicate and are 
expressed as counts per minute.
Panel b; aliquots of the immunoprecipitated IgM secreted from tritiated mannose 
labelled 4A3 cells were reduced and subjected to SDS-PAGE (10% (W/V) 
acrylamide) and fluorography. CON refers to control; TM: tunicamycin; TM-1, -2 
and -3 are analogues tunicamycin-1, -2 and -3, respectively.
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TM-3 395 + 2 0  1 9 3 + 8
^H-tnannose l a b e l l i n g  o f  jj c h a i n s
o
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observed from the fluorograph of immunoprecipitates of secretory IgM analysed by 
SDS-polyacrylamide gel electrophoresis (figure 9, panel b). Bands of similar 
migration are detected in all of the tracks except that loaded in immunoprecipitate of 
samples synthesized in the presence of normal unmodified tunicamycin.
3.1.5. Biosynthesis and Transport of IgM.
4A3 cells were pre-incubated in the absence and presence of tunicamycin 
or its analogues at 37°C for three hours, pulsed with 3 5S-methionine for one hour, 
and chased with complete RPMI for the indicated time intervals.
Figure 10 illustrates a kinetic analysis of the secretion of IgM from 4A3 
cells. Although the tunicamycin-3 analogue can apparently decrease the rate at 
which IgM is secreted from the cells, normal tunicamycin-treated 4A3 cells show 
very little, if any, export of IgM over a 6  hour chase. Beyond this time point, any 
secretion may be attributable more to cell death and lysis rather than to an active 
export process.
Figure 11 shows the SDS-PAGE profile of isolated IgM from cell lysates 
and supernatants of 4A3 cells. In the lysates, only normal tunicamycin (lane B) 
gives rise to a lower-Mr species of ji-heavy chain. The analogues (lanes C,D and E) 
have no effect upon the electrophoretic mobility of the isolated p-chains. With 
respect to secreted IgM, very little is specifically immunoprecipitable immediately 
following the pulse (0 hour), but significant amounts of IgM are precipitable from 6  
hour chase supernatants in control (lane A) and analogue-treated (lanes C,D and E) 
culture supernatants. Only in the case of normal tunicamycin-treated cells is there an 
absence of IgM in the supernatant of 4A3 cells. The extra light chain bands that are 
visualized in the SDS-PAGE profile of immunoprecipitated IgM are due to 
synthesis encoded by the parent myeloma used in the generation of this hybridoma.
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Figure 10. Kinetics of IgM secretion from treated 4 A3 cells.
4A3 cells were pre-incubated with tunicamycin or analogues and pulsed with 
150jiCi of [3 5 S]-methionine and chased for the indicated periods. Aliquots of 
immunoprecipitates prepared from culture supernatants at the indicated times were 
spotted onto glass fibre discs and precipitated with ice-cold 10% (W/V) 
trichloroacetic acid. Dried discs were analysed by liquid scintillation spectrometry. 
All determinations were made in triplicate.
KEY:
O - control
□ - normal tunicamycin-treated 
A - tunicamycin-1-treated 
▲ - tunicamycin-2 -treated 
•  - tunicamycin-3-treated
Pulse Time of
(1hr) (hrs)
chase
Figure 11. SDS-PAGE profiles of IgM isolated from 4A3 cell lysates and 
supernatants.
4A3 cells were pre-treated with tunicamycin or analogues and pulsed with 150pCi 
of p 5S]-methionine and chased for the indicated periods. Aliquots of the washed 
immunoprecipitates were run on a 10% (W/V) acrylamide gel following reduction.
KEY;
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B - normal tunicamycin-treated 
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3.1.6. Biosynthesis and Transport of IgG2b-
To analyse the effects of the analogues of tunicamycin on biosynthesis 
and transport of rat hybridoma IgG2b> a pulse-chase experiment was carried out 
using I1A1.4 cells. Only native tunicamycin has any effect upon the Mr of the y- 
chain immunoprecipitated from both lysates and culture supernatants (figure 13). In 
this case, however, and consistent with previous observations in a number of 
laboratories (Hickman and Komfeld, 1978; Blatt and Haimovich, 1981), IgG 
secretion is not inhibited by tunicamycin or, in these experiments, by any of the 
three analogues (figures 12 and 13). The results are a close parallel to those of 
figures 1 0  and 1 1 , and support the hypothesis that the structure of tunicamycin 
cannot be modified without loss of inhibitory activity.
Heifetz et al. (1979) have suggested that there are two classes of 
tunicamycin binding sites on the membranous elements of the cell. The high-affinity 
sites are represented by UDP-GlcNAc:dolichyl phosphate GlcNAc-1 -phosphate 
transferase, while low affinity sites are characterized by non-specific binding of 
tunicamycin to lipid. The data may be interpreted in terms of the structure of the 
analogues (figure 7) and their abilities to interact with two classes of tunicamycin 
receptors.
A minor modification in the uracil moiety as in tunicamycin-3 appears to 
be sufficient to abolish the activity of the antibiotic. This may be explained in terms 
of ability of the modified base to effectively enter the catalytic site of the UDP- 
GlcNAc transferase. Thus, it is binding to high affinity tunicamycin receptors 
which would be predicted to be impaired by this structural modification to 
tunicamycin. Tunicamycin-3 might be expected to behave as a competitive inhibitor 
of the transferase, but it may be bound in the transferase active site with only very 
low affinity, and be readily displaced by UDP-GlcNAc molecules themselves, with
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Figure 12. Kinetics of IgG secretion from I1A1.4 cells.
Treatment and analysis of immunoprecipitates were performed exactly as described 
in the legend to figure 3.1.4. All determinations were made in triplicate.
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Figure 13. SDS-PAGE profiles of IgG isolated from I1A1.4 cell lysates and 
supernatants.
I1A1.4 cells were pre-treated with tunicamycin or analogues and pulsed with 
150pCi of [3 5 S]-methionine and chased for the indicated periods. Aliquots of 
washed immunoprecipitates were run on a 10% (W/V) acrylamide gel following 
reduction.
KEY:
A - control
B -normal tunicamycin-treated 
C - tunicamycin-1-treated 
D - tunicamycin-2-treated 
E - tunicamycin-3-treated
0 hr 6 hr
Lysates Supernatant Supernatant
the net result being no detectable inhibition of the activity of the transferase. 
Reversible competitive inhibition of the transferase by tunicamycin-3 might be 
visualized by the isolation of partially glycosylated molecules which are observed in 
IgM-producing cells which are treated with low concentrations (less than 0.5pg/ml) 
of tunicamycin (Cushley et al., 1983). In order for partially glycosylated p-chains 
to be observed with tunicamycin-3, it is predicted that high concentrations of this 
analogue would have to be employed.
Previous studies (Kuo and Lampen, 1974) have demonstrated that the 
binding of tunicamycin to yeast protoplasts can be inhibited by the inclusion of 
phospholipid in the incubation medium. Furthermore, the inclusion of phospholipid 
could inhibit tunicamycin binding only if an unsaturated fatty acid structure was 
present. The above data suggest that the lack of an unsaturated aliphatic tail in intact 
tunicamycin leads to an impairment of antibiotic activity. Neither tunicamycin-1 nor 
tunicamycin- 2  analogues have unsaturated structures in their respective aliphatic 
tails, and this particular modification may result in an inability of the analogues to 
interact with non-specific or low affinity tunicamycin binding sites. If the 
tunicamycin analogues are unable to bind to the membranous elements of the cell, 
then it is unlikely that they will be in the correct cellular compartment to interact 
with the high-affinity tunicamycin binding sites, and consequently will be unable to 
inhibit glycosylation.
Both tunicamycin-1 and tunicamycin-2 analogues possess modifications 
other than that to the aliphatic tail (see figure 7). The open ring structure at the site 
of the uracil base of tunicamycin- 1 may result in the failure of this analogue to bind 
to the transferase active site (i.e., the high-affinity tunicamycin binding sites) and an 
inability to block protein N-glycosylation. The pyranose sugar of tunicamycin-2 
may also act in a similar manner. The data suggest that minor modifications to the 
structure of the uracil moiety alone can eliminate the ability of tunicamycin to inhibit
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glycosylation. However, in the case of analogues tunicamycin-1 and tunicamycin- 
2 , it is not possible to distinguish the contribution of lipid modification and 
ribose/base modification in the loss of antibiotic activity. Further studies with other 
tunicamycin analogues may help to resolve this question.
The above data support the previous findings of Tkacz and Wong (1978) 
who demonstrated that generation of tunicamycin fragments by acid hydrolysis or 
acetolysis led to loss of ability to inhibit N-glycosylation. Their data have suggested 
that the intact tunicamycin was required for expression of antibiotic biological 
activity, and the data herein extend those observations by demonstrating that small 
modifications to the structure of intact tunicamycin can also result in loss of the 
ability of the drug to inhibit protein N-glycosylation. The data are therefore 
consistent with the interpretation that unmodified tunicamycin is required for 
expression of antibiotic inhibitory activity, and because the analogues of 
tunicamycin do not mimic its effects upon secretion of immunoglobulin molecules, 
it is also reasonable to conclude that such inhibition of transport is due not to side- 
effects of the antibiotic but to absence of carbohydrate side chains.
3.1.7. Qualitative Glycosylation.
Tunicamycin irreversibly inhibits the activity of UDP-GlcNAc:dolichyl 
phosphate GlcNAc-1-phosphate transferase, possibly by acting as a substrate- 
product transition state analogue (Heifetz et al., 1979). The discussed data suggest 
that a small modification to any of the base, aliphatic or nucleotide components of 
tunicamycin will abrogate its ability to inhibit the activity of this enzyme. However, 
a further series of UDP-N-acetylglucosamine transfer reactions occur during 
oligosaccharide processing in the Golgi apparatus (see section 1.2.2), and these N- 
acetylglucosaminyl transferase I and II activities might be subject to inhibition by 
the tunicamycin analogues.
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To address this question, immunoprecipitates of IgG molecules derived 
from lysates and supernatants of IIA 1.4 cells were subjected to endo H digestion. 
In this situation, if the tunicamycin analogues inhibit the activity of the UDP-N- 
acetylglucosaminyl transferase then a "complex", processed oligosaccharide cannot 
be generated, and a "high mannose" form of carbohydrate side chain will remain. 
Only the latter form of oligosaccharide structure is susceptible to endo H digestion 
(Tarentino etal., 1978).
Figure 14 illustrates the SDS-PAGE profile of digested and mock- 
digested immunoprecipitates derived from cell lysates. In all cases, except 
tunicamycin-treated cells, the y-chains showed susceptibility to endo H digestion. 
However, when secreted y-chains are analysed following endo H treatment, all 
forms of the heavy chain polypeptide are resistant to the action of endo H, which 
implies that the oligosaccharides present on the secreted molecules are fully 
processed and are of the complex form (figure 15). This observation suggests that 
not only do tunicamycin analogues fail to inhibit the first stage in assembly of the 
oligosaccharide-dolichol molecule, but also that they have no effect on the N- 
acetylglucosaminyl transferase I and II activities located in the Golgi apparatus.
The above study has demonstrated that modification to the structure of 
tunicamycin results in the loss of its ability to inhibit N-glycosylation. The 
analogues have also been shown to have no pronounced inhibitory effect on the 
synthesis of macromolecules. From these observations, it is therefore reasonable to 
deduce that the selective inhibition of immunoglobulin secretion and the cytotoxic 
effect that is observed when cells are treated with tunicamycin are secondary 
responses of the cell. In addition, analogous to tunicamycin, the analogues also 
have no effect on the N-acetylglucosaminyl transferases of the Golgi apparatus.
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Figure 14. Endoglycosidase H susceptibility of intracellular IgG derived from 
I1A1.4 cells.
Purified immunoprecipitates of IIA 1.4 cell lysates were treated with 
endoglycosidase H (+) or with buffer only (-). CON refers to control; TM: 
tunicamycin; TM-1, -2 and -3 are analogues tunicamycin-1, -2 and -3, respectively.
I n t r a c e l l u l a r
Figure 15. Endoglycosidase H susceptibility of secretory IgG derived from I1A1.4 
cells.
Purified immunoprecipitates of IIA 1.4 culture supernatants were treated with 
endoglycosidase H (+) or with buffer only (-). CON refers to control; TM: 
tunicamycin; TM-1, -2 and -3 are analogues tunicamycin-1, -2 and -3, respectively.
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SECTION 3.2.
N-LINKED OLIGOSACCHARIDE PROCESSING INHIBITION - EFFECTS 
ON SECRETION OF RAT HYBRIDOMA IMMUNOGLOBULINS.
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3.2.1. Processing Inhibition of N-Linked Oligosaccharides of IgM.
4A3 cells were treated with the indicated concentrations of processing 
inhibitors for one hour prior to pulse chase and immunoprecipitate preparation. 
Incorporation of radioactivity was determined by counting 5pl aliquots of 
immunoprecipitates. Figure 16 demonstrates the kinetics of IgM secretion from 
various N-linked oligosaccharide processing inhibitor-treated 4A3 cells. With the 
exception of SW-treated cells, which exhibit a slightly reduced rate of secretion, the 
rates of export of IgM from 4A3 cells treated with the other processing inhibitors 
are comparable to that observed for control cells. No appreciable secretion of IgM 
was detected from TM-treated 4A3 cells.
3.2.1.1. IgM Secretion; L Castanospermine.
The kinetic data are supported by the individual SDS-PAGE profiles of 
radioactive bands of immunoprecipitated material. Figure 17, panel a, shows the 
analysis of IgM secreted from CSP-treated 4A3 cells. The fluorographic intensity of 
p-chain bands can be seen to increase with time of chase for both control and CSP- 
treated samples. This is in agreement with kinetic data which suggest that treatment 
of 4A3 cells with CSP does not result in any changes to the rate of export of IgM. 
However, the electrophoretic mobility of the p-chains immunoprecipitated from 
cultures of CSP-treated cells is slower than that of the p-chains derived from control 
cultures. A similar observation has been earlier reported in experiments using CSP 
(Peyrieras et al., 1983; Pan et al., 1983; Hori et al., 1984). The higher Mr p- 
chains secreted in the presence of CSP has been suggested to be due to the presence 
of precursor-type oligosaccharide structures.
Effect of treatment with CSP is further demonstrated by endo H analysis 
of the immunoprecipitated IgM (figure 17, panel b). p-chains of samples from 
untreated culture supernatant are observed to be partially resistant to the enzyme
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Figure 16. Kinetics of IgM secretion from N-linked oligosaccharide processing 
inhibitor-treated 4A3 cells.
Aliquots of immunoprecipitate derived from culture supernatants at the indicated 
times were spotted onto filter discs, and counted by liquid scintillation 
spectrometry. All determinations were performed in triplicate. Panel A: CSP- 
treated, B: dNM-treated, C: dMM-treated andD: SW-treated. In each panel ( o  - 
O) represents control, ( A - A ): processing inhibitor-treated and ( □ - □ ) :  TM- 
treated.
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Figure 17. Analysis of IgM secreted from Castanospermine-treated 4A3 cells.
Panel a; Aliquots of immunoprecipitate prepared from either cell lysates or 
supernatants from 4A3 cultures treated with CSP were boiled in sample buffer 
containing 2-mercaptoethanol and electrophoresed on 10% (W/V) acrylamide slab 
gels. Numbers for supernatant samples refer to duration of chase in hours.
Panel b\ Small portions of immunoprecipitate prepared from 4 hour chase 
supernatants was precipitated with 5 volumes of acetone and resuspended in a small 
volume of 50mM citrate buffer, pH 5.5, containing 0.1% (W/V) SDS. 5 milliunits 
of endo H were added and the sample incubated at 37°C for 18 hours; a non­
digested control was also prepared. Samples were analysed on 10% (W/V) 
acrylamide slab gels. Lysate (lanes a-f) and supernatant (lanes g-j) samples, both 
endo H-treated (+) (lanes b, d, f, h and j) and untreated controls (-) (lanes a, c, e, g 
and i) were analysed for each of control, TM- and CSP-treated cultures.
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treatment (lane h). This is because a single p-chain generally contains five r e ­
linked oligosaccharide moieties which exist as a mixture of complex and high 
mannose forms (see figure 5). Thus, partial endo H susceptibility is a result of the 
presence of these high mannose oligosaccharide structures in IgM. The p-chains 
secreted in the presence of CSP are, however, fully susceptible to the enzyme 
treatment (lane j) indicating modified non-complex-type N-linked oligosaccharide 
structures.
3.2.I.2. IgM Secretion; n. 1-Deoxynojirimycin.
The electrophoretic mobility of p-chains resolved by SDS-PAGE of 
reduced immunoprecipitates isolated from dNM-treated cells are illustrated in figure 
18, panel a. In this case, however, there appear not to be any differences in the 
electrophoretic mobilities of p-chains derived from dNM-treated cells to that of 
control cells. This is most likely due to the insufficient resolution of the bands since 
immunoprecipitate samples were subjected to a much shorter gel electrophoresis. In 
other cases, immunoglobulin heavy chains that are isolated from cells exposed to 
dNM demonstrate slower Mr electrophoretic migration as compared to control 
samples (e.g., see figure 23). The data, however, demonstrate that inactivation of 
cellular glucosidase I and II activities does not impair the secretion of IgM from 
4A3 cells.
Endo H digestion analysis of the untreated and dNM-treated IgM 
immunoprecipitates confirms the effects of the sugar analogue on N-linked 
oligosaccharide processing; while the p-chains isolated from the dNM-treated 
culture supernatants are susceptible to the enzyme (lane j), control p-chains are 
resistant (lane h, figure 18, panel b). Intracellular immunoglobulins are, however, 
susceptible to the enzyme treatment in both cases (lanes b and d).
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Figure 18. Analysis of IgM secreted from 1-deoxynojirimycin-treated 4A3 cells.
Panel a; SDS-PAGE analysis of immunoprecipitated IgM from dNM-treated 4A3 
cells was performed on 10% (W/V) acrylamide gels as described in the legend to 
figure 17(a).
Panel b; Endo H digestion of immunoprecipitates prepared from aliquots of cell 
lysates or from 4 hours chase supernatants and analysis was performed as 
described in the legend to figure 17(b).
Endo H treatment of control secreted samples in this case demonstrates that carbohydrate 
moieties of the IgM are resistant to enzymatic cleavage. This is quite unexpected and 
differs from other data that show that carbohydrate moieties of IgM are partially susceptible 
to the enzyme due to the presence of high mannose N-linked oligosaccharide moieties. 
This may be due to the fact that the IgM may have not been completely denatured (a 
requirement for the enzyme to act) or that the enzyme that was used may have lost its 
activity.
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3.2.1.3. IgM Secretion; HL 1-Deoxymannojirimydn.
Figure 19, panel a, demonstrates the fluorograph of a similar pulse-chase 
experiment performed in the presence of the mannosidase Ia/b inhibitor, dMM. 
Intensity of the p-chain bands increases with the time of chase. However, there is 
no difference in the electrophoretic mobility of the p.-chains immunoprecipitated 
from cultures of dMM-treated cells with that of the p-chains derived from control 
cultures. This is compatible with earlier findings from studies using this drug (see 
section 1.3.2.3). A similar result is also obtained from the endo H digestion 
analysis (figure 19, panel b). While control p-chains exhibit partial susceptibility to 
the enzyme (lane h), total susceptibility is seen in the case of p-chains isolated from 
the mannosidase Ia/b inhibitor-treated culture supernatants (lane j).
3.2.1.4. IgM Secretion; IV. Swainsonine.
In the case of pulse-chase experiment with SW-treated 4A3 cells, identical 
electrophoretic resolution to that achieved in the presence of dMM was obtained 
(figure 20, panel a). The p-chain bands are observed to increase in intensity 
accordingly with duration of chase. The effect of the mannosidase II inhibitor is 
further confirmed by the endo H analysis since, unlike the partially digested p- 
chains secreted from control cells (lane h), p-chains secreted in the presence of the 
drug are fully susceptible to the enzyme (lane j, figure 2 0 , panel b).
The data from pulse-chase experiments carried out on 4A3 cells clearly 
demonstrate that inhibition of the processing of N-linked oligosaccharide at various 
stages of the pathway (glucosidase and mannosidase activities) does not lead to any 
significant interference with the rate of IgM secretion. The data fully support that 
previously reported by Peyrieras et al. (1983) and Fuhrmann et al. (1984), i.e., 
inhibition of oligosaccharide processing in B1.8p cells by dNM, dMM and SW 
does not affect the secretion of IgM molecules. However, The B1.8p cell line used 
in their study is unique and does not provide a suitable model for transport analysis.
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Figure 19. Analysis of IgM secreted from 1-deoxymannojirimycin-treated 4 A3 
cells.
Panel a; SDS-PAGE analysis of immunoprecipitated IgM from dMM-treated 4A3 
cells was performed on 10% (W/V) acrylamide gels as described in the legend to 
figure 17(a).
Panel b\ Endo H digestion of immunoprecipitates prepared from aliquots of cell 
lysates or from 4 hours chase supernatants and analysis was performed as 
described in the legend to figure 17(b).
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Figure 20. Analysis of IgM secreted from Swainsonine-treated 4A3 cells.
Panel a; SDS-PAGE analysis of immunoprecipitated IgM from SW-treated 4A3 
cells was performed on 10% (W/V) acrylamide gels as described in the legend to 
figure 17(a).
Panel b\ Endo H digestion of immunoprecipitates prepared from aliquots of cell 
lysates or from 4 hours chase supernatants and analysis was performed as 
described in the legend to figure 17(b).
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The carbohydrate moieties of the IgM synthesized from the cell line have been 
reported not to be crucial for maintaining immunoglobulin secretion (Vasilov and 
Ploegh, 1982). Since IgM of B1.8|i can apparently be secreted in the non-N- 
glycosylated state, it is unlikely that inhibition of oligosaccharide processing would 
block secretion.
The study that was carried out using 4A3 cells is more definitive in that 
the cell line is compatible with most other IgM producing cells with respect to the 
importance of its carbohydrate moieties in controlling transport. Inhibition of N- 
glycosylation of IgM from 4A3 cells leads to blockade in secretion (see section 
3.1.5). Thus, results that were obtained from the oligosaccharide processing 
inhibition experiments are more conclusive than those that have been previously 
reported. In addition, the above data also extends the existing observation by 
demonstrating that interference with CSP also fails to block intracellular transport of 
IgM.
3.2.2. Processing Inhibition of N-Linked Oligosaccharides of IgG.
IIA 1.4 cells were treated with the indicated concentrations of processing 
inhibitors. After pulse-chase, IgG was isolated from aliquots of lysate and 
supernatant of the cells by immunoprecipitation. Incorporation of radioactivity was 
determined by counting 5pl aliquots of immunoprecipitates. Figure 21 shows a 
kinetic analysis of the secretion of IgG from control and processing inhibitor-treated 
II A1.4 cells. Treatment of the cells with SW appears to result in a slightly enhanced 
secretion. The rates of export of IgG from IIA 1.4 cells treated with the other 
processing inhibitors are identical to those observed for control cells.
3.2.2.1 IgG Secretion; L Castanospermine.
The SDS-PAGE profiles of IgG component polypeptides isolated from
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Figure 21. Kinetics of IgG secretion from N-linked oligosaccharide processing 
inhibitor-treated I1A1.4 cells.
Aliquots of immunoprecipitate derived from culture supernatants at the indicated 
times were spotted onto filter discs, and counted by liquid scintillation 
spectrometry. All determinations were performed in triplicate. Panel A: CSP- 
treated, B: dNM-treated, C: dMM-treated and D: SW-treated. In each panel (O - 
O) represents control and ( A - A): processing inhibitor-treated.
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control, CSP- and TM-treated cultures are illustrated in figure 22, panel a. The data 
demonstrate that CSP-treatment does not result in any decrease in the rate of export 
of IgG from cells exposed to the alkaloid, and the Mr of the y-chain isolated from 
the culture supernatants is slightly greater than that of control y-chains.
The oligosaccharide structure present on the IgG2b molecules secreted by 
I1A1.4 cells is complex in form and is resistant to endo H digestion (see section 
3.1.7). Figure 22, panel b, illustrates that following treatment with CSP, the 
intracellular form of the y-chain in the treated cells shows susceptibility to endo H, 
and also that those isolated from the culture supernatants are also digested by the 
enzyme. The data suggest that CSP has inhibited the glucosidase activity of II A1.4 
cells, since the treated cells have not converted the N-linked oligosaccharides to a 
complex, endo H-resistant state in a manner analogous to control, untreated cells. 
The data are consistent with the notion that CSP can inhibit processing of the N- 
linked oligosaccharides of the IgG molecule, but that such interference does not 
impair secretion of IgG from treated cells.
3.2.2.2. IgG Secretion; IL 1-Deoxynojirimycin.
Figure 23, panel a, shows the SDS-PAGE profiles of IgG isolated from 
control, dNM- and TM-treated IIA 1.4 cultures, respectively. The data show a 
similar trend to that obtained using CSP, i.e., dNM-treatment does not result in any 
decrease in the rate of export of IgG from cells and may indeed cause a slight 
increase in the kinetics of IgG secretion. The y-chains isolated from lysates or 
supernatants of dNM-treated cells also exhibit a slightly slower electrophoretic 
mobility relative to control y-chains.
Figure 23, panel b, demonstrates that dNM treatment alters susceptibility
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Figure 2 2 . Analysis of IgG secreted from Castanospermine-treated I1A1.4 cells.
Panel a; Aliquots of immunoprecipitate prepared from either cell lysates or 
supernatants from I1A1.4 cultures treated with CSP were boiled in sample buffer 
containing 2-mercaptoethanol and electrophoresed on 10% (W/V) acrylamide slab 
gels. Numbers for supernatant samples refer to duration of chase in hours.
Panel b; Small portions of immunoprecipitate prepared from 4 hour chase 
supernatants was precipitated with 5 volumes of acetone and resuspended in a small 
volume of 50mM citrate buffer, pH 5.5, containing 0.1% (W/V) SDS. 5 milliunits 
of endo H were added and the sample incubated at 37°C for 18 hours; a non­
digested control was also prepared. Samples were analysed on 10% (W/V) 
acrylamide slab gels. Lysate (lanes a-f) and supernatant (lanes g-1) samples, both 
endo H-treated (+) (lanes b, d, f, h, j and 1) and untreated controls (-) (lanes a, c, e, 
g, i and k) were analysed for each of control, TM- and CS P-treated cultures.
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Figure 23. Analysis of IgG secreted from 1-deoxynojirimydn-treated I1A1.4 cells.
Panel a; SDS-PAGE analysis of immunoprecipitated IgG from dNM-treated 
I1A1.4 cells was performed on 10% (W/V) acrylamide gels as described in the 
legend to figure 2 2 (a).
Panel b; Endo H digestion of immunoprecipitates prepared from aliquots of cell 
lysates or from 4 hours chase supernatants and analysis was performed as 
described in the legend to figure 2 2 (b).
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of the y-chain to endo H digestion. While control secreted y-chains are resistant to 
the effects of the enzyme, IgG secreted from dNM-treated cells contains y-chains 
which are susceptible to digestion by endo H. The data therefore parallel those 
obtained from studies with CSP in illustrating that while dNM can prevent 
oligosaccharide processing and thereby alter the qualitative structure of the N-linked 
glycans of the IgG molecule, it has no inhibitory effect upon secretion of IgG from 
the cell.
3.2.2.3. IgG Secretion; in . 1-Deoxymannojirimycin.
Figure 24, panel a, demonstrates the fluorograph of pulse-chase 
experiment carried out in the presence of dMM. There is no difference in the 
electrophoretic mobility of the y-chains immunoprecipitated from cultures of the 
sugar analogue-treated cells with that of the y-chains derived from control cultures. 
Intensity of the y-chain bands also corresponds with the increasing time of chase. 
Result from the endo H analysis on the immunoprecipitated IgG produced from 
control, dMM- and TM-treated IIA 1.4 cells is illustrated in figure 24, panel b. The 
carbohydrate chains of IgG secreted in the presence of the mannosidase Ia/b 
inhibitor has been structurally modified as demonstrated by the y-chains 
susceptibility to endo H digestion (lane j).
3.2.2.4. IgG Secretion; IV. Swainsonine.
Pulse-chase experiments with I1A1.4 cells treated with SW yield similar 
results. Identical electrophoretic resolution to that done in the presence of dMM was 
obtained (figure 25, panel a). Modification of the N-linked oligosaccharides of IgG 
synthesized in the presence of this processing inhibitor is further confirmed by the 
endo H analysis where only the drug-treated sample is fully susceptible to the 
enzyme (lane j, figure 25, panel b).
The data obtained from experiments using IIA 1.4 cells demonstrate that
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Figure 24. Analysis of IgG secreted from 1-deoxymannojirimycin-treated I1A1.4 
cells.
Panel a; SDS-PAGE analysis of immunoprecipitated IgG from dMM-treated 
IIA 1.4 cells was performed on 10% (W/V) acrylamide gels as described in the 
legend to figure 2 2 (a).
Panel b\ Endo H digestion of immunoprecipitates prepared from aliquots of cell 
lysates or from 4 hours chase supernatants and analysis was performed as 
described in the legend to figure 2 2 (b).
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Figure 25. Analysis of IgG secreted from Swainsonine-treated I1AI.4 cells.
Panel a; SDS-PAGE analysis of immunoprecipitated IgG from SW-treated I1A1.4 
cells was performed on 1 0 % (W/V) acrylamide gels as described in the legend to 
figure 2 2 (a).
Panel b\ Endo H digestion of immunoprecipitates prepared from aliquots of cell 
lysates or from 4 hours chase supernatants and analysis was performed as 
described in the legend to figure 2 2 (b).
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the rate of secretion of IgG is not diminished by inhibition of either glucosidase or 
mannosidase activities. Since IgG can be efficiently secreted in the non-N- 
glycosylated state (see table 1 ), it is unlikely that inhibition of oligosaccharide 
processing would block secretion. Such a possibility is, however, not totally 
excluded, as has been demonstrated in case of the IgD of the B1.88 cells. While 
transport of the non-N-glycosylated IgD is efficiently maintained (Vasilov and 
Ploegh, 1982), inhibition of glucosidase I and II activities by dNM lead to 
markedly impaired immunoglobulin export (Peyrieras et al., 1983). The effects of 
carbohydrate processing inhibition by CSP on the expression of membrane-form 
immunoglobulins are also similarly observed. Membrane-form IgD cell surface 
expression is markedly retarded in the presence of the glucosidase inhibitor but is 
not affected in the presence of mannosidase inhibitors (Cushley et al., personal 
communication).
The capacity of dNM to inhibit secretion is apparently random with the 
secretion of al-antichymotrypsin and a j-antitrypsin, but not transferrin, albumin or 
C3, from the human HepG-2 cell line being inhibited (Lodish and Kong, 1984). 
Similarly, in rat hepatocytes, dNM treatment inhibited the secretion of a  j-acid 
glycoprotein and a j-proteinase inhibitor by approximately 50%. CSP treatment, 
however, caused no appreciable inhibition of secretion of any of these 
macromolecules from the hepatocytes (Gross et al., 1986). CSP also has 
apparently selective effects upon secretion of proteins from hepatocytes. For 
example, the secretion of a  j-antitrypsin, caeruloplasmin and, to a much lesser 
extent, anti thrombin III can be inhibited by CSP treatment. In the same cells, 
however, the rates of secretion of the protein albumin and of the exclusively O- 
glycosylated glycoprotein apolipoprotein E were not affected.
Exposure to mannosidase inhibitors have, however, resulted in consistent
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observations, i.e., their interference does not lead to any retardation of glycoprotein 
export (Peyrieras et al., 1983; Fuhrmann et al., 1984; Gross et al., 1985; 
Hashim and Cushley, 1987b). Indeed, several groups have observed that the export 
of glycoproteins can apparently be accelerated in the presence of SW (Yeo et al., 
1985; Fuhrmann et al., 1985). In hepatocytes, the rates of secretion of 
caeruloplasmin and a 2 -macroglobulin were increased, but not those of transferrin, 
albumin or a 1-antitiypsin (Yeo et al., 1985).
The data obtained from this study may be interpreted in terms of the 
overall sensitivity of a given immunoglobulin isotype to interference with 
glycosylation as assessed by ultimate secretory fate. For example, treatment of B 
cell lines with tunicamycin results in different effects upon secretion depending on 
the isotype of the immunoglobulin synthesized by the cell line. Many laboratories 
have observed that IgM secretion is inhibited by tunicamycin treatment, but IgG 
secretion proceeds quite efficiently (see table 1). This may be reflected in the 
experiments with S W, where the secretion of IgM, but not IgG, is slightly retarded 
by the presence of the mannosidase II inhibitor. The two most obvious explanations 
which could be advanced to account for the data would be the number of 
oligosaccharide groups per heavy chain, and the overall size and solubility of the 
assembled immunoglobulin (19S IgG as opposed to 7S IgG). Neither of these 
views can be readily accommodated with data obtained from hepatocytes systems. 
Thus, both a 2-macroglobulin and caeruloplasmin are high molecular weight, 
multiply N-glycosylated molecules, and the secretion of both is potentiated rather 
than retarded by SW.
3.2.3. Simultaneous Inhibition of N-linked Oligosaccharide Processing of IgM
and IgG.
The data from the above SDS-PAGE analysis, however, do not reveal the
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precise structures that evolved from manipulations involving use of individual r e ­
linked oligosaccharide processing inhibitors. Several reports have already described 
that inhibition of carbohydrate processing by using CSP, dNM or SW does not 
totally prevent further modification reactions (Peyrieras et al., 1983; Tulsiani et 
al., 1983; Gross et al., 1986). Terminal carbohydrate branches that are not 
affected by the actions of the processing inhibitor are normally further processed 
and may indeed be transformed to the complex type structures. Thus, if N-linked 
oligosaccharide moieties may be partly processed and undergo complex conversion 
reactions, there is still a possibility of configurations that are generated becoming 
involved in the putative ligand-receptor-mediated transport processes. Accordingly, 
a study assessing the effects of simultaneous inhibition of glucosidase and 
mannosidase activities, which theoretically assures complete prevention of complex 
conversion reactions, on the export of rat hybridoma IgM and IgG was carried out.
Figure 26 demonstrates the kinetics of IgM (panels a, b and c) and IgG 
(panels d, e and f) secretion in the presence of mixtures of processing inhibitors. 
Cells were exposed to the mixtures of processing inhibitors prior to the routine 
pulse-chase procedures. The data demonstrate that, in all cases, simultaneous 
blockade of the glucosidase and mannosidase activities does not interfere with the 
rate of immunoglobulin secretion from rat hybridoma cells.
3.2.3.1. SDS-PAGE Analysis of Mixtures of Inhibitors-Treated 4A3 and I1A1.4
Cells.
The SDS-PAGE profiles of IgM component polypeptides isolated from 
control and mixtures of processing inhibitors-treated cultures are illustrated in figure 
27; panels a: dNM/dMM, b: CSP/SW and e: CSP/dNM/dMM/SW (41 in figure). 
The data demonstrate that simultaneous blockade of multiple steps involved in the 
processing of N-linked oligosaccharides of the immunoglobulin ji-chains does not 
impair the rate of IgM secretion from 4A3 cells. Intensity of p.-chain bands is
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Figure 26. Kinetics of IgM and IgG secretion from cells treated with mixed 
oligosaccharide processing inhibitors.
Aliquots of immunoprecipitate derived from culture supernatants at the indicated 
times were spotted onto filter discs, and counted by liquid scintillation 
spectrometry. All determinations were performed in triplicate. Panels a, b and c 
were counts obtained from immunoprecipitated IgM molecules. Panels d, e and/  
were counts obtained from immunoprecipitated IgG molecules.
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Figure 27. SDS-PAGE profiles of immunoglobulins isolated from cultures treated 
with mixtures of oligosaccharide processing inhibitors.
Aliquots of immunoprecipitate prepared from either cell lysates or supernatants 
from 4A3 and IIA 1.4 cultures exposed to mixtures of processing inhibitors were 
boiled in sample buffer containing 2 -mercaptoethanol and electrophoresed on 1 0 % 
(W/V) acrylamide slab gels. Numbers for supernatant samples refer to duration of 
chase in hours. Panels a and b demonstrate the heavy and light chains of 
immunoglobulins secreted from 4A3 cells treated with dNM/dMM and CSP/SW, 
respectively. Continue on next page...
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.. .continuation of figure 2 7.
Panels c and d demonstrate the heavy and light chains of immunoglobulins 
secreted from IIA 1.4 cells treated with dNM/dMM and CSP/SW, respectively. 
Panels e (4A3) and /  (I1A1.4) show the SDS-PAGE resolution of 
immunoglobulins isolated from cells treated with all of the processing inhibitors 
(i.e., CSP/dNM/dMM/SW or 41).
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observed to increase with the time of chase. In all cases, however, \i -chains that 
were isolated from culture supernatant of treated cells migrated more slowly than 
those of untreated cells.
Panels c, d and f of the same figure demonstrate the electrophoretic 
mobilities of y-chains isolated from mixtures of inhibitors-treated I1A1.4 cells 
resolved by SDS-PAGE (panels c: dNM/dMM, d: CSP/SW and f: 
CSP/dNM/dMM/SW, i.e., 41 in figure). As in IgM from 4A3 cells, the export of 
IgG from IIA 1.4 cells is not affected when exposed to the mixtures of the 
processing inhibitors. Also observed in all cases is the retarded electrophoretic 
migration of y-chains isolated from mixtures of drugs-treated cells.
3.2.3.2. Endo H Analysis of Mixtures of Inhibitors-Treated 4A3 and I1A1.4 Cells.
Aliquots of immunoprecipitates of IgM and IgG that were isolated from 
cultures of cells that were exposed to the mixtures of processing inhibitors and their 
respective controls were subjected to endo H analysis as described in section 2.6.1. 
The individual enzyme- and mock-treated samples were then reduced and resolved 
by SDS-PAGE. Figure 28 demonstrates that when exposed to the series of the 
processing inhibitors, p- and y-chains that were secreted are susceptible to the 
enzyme digestion.
The principal finding from the analysis that was carried out by 
simultaneously inhibiting the multiple steps involved in the processing of N-linked 
oligosaccharides of immunoglobulins is that such interference has no inhibitory 
effect upon the secretion of immunoglobulins from rat hybridoma cells. In all cases 
studied, however, the qualitative structure of the oligosaccharides present on the 
immunoglobulins was different from controls as determined by susceptibility to 
endo H digestion and by the Mr of the isolated immunoglobulin heavy chains on
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Figure 28. Endo H analysis of mixtures of oligosaccharide processing inhibitors- 
treated 4A3 and I1A1.4 cells.
Endo H digestion of immunoprecipitates prepared from aliquots of cell lysates or 
from 4 hours chase supernatants and analysis was performed as described in the 
legend to figure 22(b). Panels a and b demonstrate the endo H analysis of 
immunoglobulins secreted from 4A3 cells treated with mixtures of alkaloids 
(CSP/SW) or sugar analogues (dNM/dMM). Continue on next page...
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...continuation o f figure 28.
Panels c and d demonstrate the endo H analysis of immunoglobulins secreted 
from IIA 1.4 cells treated with mixtures of sugar analogues (dNM/dMM) and 
alkaloids (CSP/SW). Panels e (I1A1.4 cells) and /  (4A3 cells) demonstrate 
analysis of immunoglobulins from cells exposed to all of the processing inhibitors, 
i.e., lanes c, d, g, h, k, 1, o and p (CSP/dNM/dMM/SW). Lanes a, b, e, f, i, j, m 
and n are their respective controls.
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SDS-PAGE.
Resolution of the ji- and ^ chains that were derived from treated cells by 
SDS-PAGE reveals that all possess a higher Mr relative to their counterparts 
immunoprecipitated from control cultures. This is especially pronounced in the case 
of p.-chains derived from 4A3 cells (figure 17). This higher Mr form of p.- and y- 
chains has been previously observed in cells treated with either of the glucosidase 
inhibitors, i.e., CSP or dNM (figures 17, 22 and 23; Peyrieras et al., 1983). 
Given that higher Mr forms of p- and y-heavy chains can be detected when cells are 
exposed simultaneously to glucosidase and mannosidase inhibitors suggests that 
treatment with glucosidase inhibitors may be rate limiting with respect to generation 
of substrate configurations for later steps in the processing pathway.
The data have significant implications for the involvement of 
oligosaccharide processing enzymes in overall regulation of glycoprotein secretion. 
Kelly and co-workers (Gumbiner and Kelly, 1982; Moore and Kelly, 1985) have 
suggested that glycoproteins can be secreted by two distinct cellular pathways, a 
constitutive pathway (which operates continuously), or by regulatory pathway in 
which the export of particular proteins is subject to strict control. By such a 
classification, immunoglobulins when secreted by hybridomas, would be a member 
of that category of secretory glycoproteins which are exported via the constitutive 
pathway. This is supported by the evidence that the processing of N-linked 
oligosaccharides that occurs as immunoglobulin traverses the rough endoplasmic 
reticulum and Golgi apparatus does not have any regulatory function in controlling 
secretion (Peyrieras et al., 1983; Fuhrmann et al., 1985; this thesis). Further 
support of this notion comes from the work of Tartakoff and Vassalli (1977 and 
1978) who have demonstrated that unlike cells that follow the regulatory pathway, 
export of immunoglobulins from actively-secreting plasma cells are not affected by
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depletion of extracellular calcium, or by addition of hormones, cyclic nucleotide 
derivatives, or agents acting on microtubules or microfilaments.
The lack of involvement of oligosaccharide processing in control of 
secretion has been observed for many glycoproteins other than immunoglobulins 
(Franc et al., 1986; Gross et al., 1986), although there are some glycoproteins, 
for example, a  j-antitrypsin, a  j-antichymotiypsin and caeruloplasmin from HepG-2 
cells (Lodish and Kong, 1984; Sasak et al., 1985), whose secretion can be 
retarded by glucosidase inhibitors. The apparent division of glycoproteins into 
categories whose secretion are respectively sensitive or insensitive to inhibition of 
oligosaccharide processing supports the notion of two secretory pathways. 
However, an interesting question arises as to whether proteins which belong to a 
constitutive pathway in one state of differentiation of their biosynthesis cell, are 
members of that same pathway in all developmental forms of that cell. The data 
from this thesis and others with regard to immunoglobulin secretion (Peyrieras et 
al., 1983; Fuhrmann et al., 1984), have been made in hybridomas which are fully 
committed to secretion, and may not be valid for other differentiation states of B 
cells (e.g., lymphoma cells), where immunoglobulin secretion is a lower metabolic 
priority for the cell.
Support for this proposal is provided by the finding that mannosidase 
inhibitors can block the development of human B cells (Tulp et al., 1986). Using 
human peripheral blood mononuclear cells stimulated by mitogens, it was noted that 
the presence of SW or dMM at the start of the culture or their addition up to 24 
hours after initiation of culture of the lymphocytes with the mitogens inhibited IgM 
and IgG production assessed at day 5. The effect was apparently a specific block in 
the development of B cells to antibody-secreting cells and not a toxic effect of the 
inhibitors. Furthermore, the effect was only observed if the inhibitors were added 
early in the culture since immunoglobulin secretion from cells treated with SW or
1 0 9
dMM on day 5 of culture was not impaired, suggesting a differentiation state- 
dependent effect
Several conclusions may be derived from the preceding studies involving 
use of oligosaccharide processing inhibitors. The data clearly demonstrate that 
inhibition of the processing of N-linked oligosaccharide at specific stages of the 
pathway, or by using all of the oligosaccharide processing inhibitors 
simultaneously, does not lead to any significant interference with the rate of IgM 
and IgG2b secretion. Different structures of oligosaccharide chains are, however, 
synthesized from cells exposed to the oligosaccharide processing inhibitors. This is 
demonstrated from their susceptibility to endo H enzyme. In case of 
immunoglobulins synthesized in the presence CSP, dNM or mixtures of inhibitors 
containing either of the glucosidase I and II inhibitors, the structural difference is 
further demonstrated by the relatively heavier Mr heavy chains shown by their 
SDS-PAGE resolution.
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SECTION 3.3.
N-LINKED OLIGOSACCHARIDE PROCESSING INHIBITION - 
STRUCTURAL ANALYSIS OF CARBOHYDRATE MOIETIES AND EFFECTS 
ON SECONDARY FUNCTIONS OF RAT IIYBRIDOMA IgG2b.
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3.3.1. Neuraminidase Digestion Analysis.
The specific site(s) of action of the various oligosaccharide processing 
inhibitors that are used in this study are well documented (see sections 1.3.2.1 - 
1.3.2.4). However, the precise structures of carbohydrate moieties that are 
generated when cells are exposed to these inhibitors are not clearly defined. The 
only common criteria that oligosaccharide moieties have when produced in the 
presence of the processing inhibitor is their susceptibility to the endo H enzyme, 
which often lead to their being generally classified as having "high mannose" 
structures. Although endo H is known not to act on the complex-type 
oligosaccharide structures, its precise mechanisms of action on the other wide 
variations of oligosaccharide structures are not well understood (Fuhrmann et al., 
1985).
An attempt was made to identify the N-linked oligosaccharide structures 
of immunoglobulins that are secreted in the presence of the oligosaccharide 
processing inhibitors. Figure 29 demonstrates the neuraminidase analysis of 
immunoprecipitated IgG2b secreted from IIA 1.4 cells that were exposed to the 
oligosaccharide processing inhibitors. In control (i.e., untreated) samples, the 
isolated IgG2b molecules from IIA 1.4 culture supernatant demonstrate resistance to 
the enzyme. This suggests that under normal conditions, immunoglobulins that are 
secreted from I1A1.4 cells have no terminally-linked sialic acid residues. However, 
when the cells are treated with the processing inhibitors, a fraction of the 
immunoprecipitated immunoglobulins demonstrates susceptibility toward 
neuraminidase digestion, suggesting the presence of sialic acid units on some of the 
immunoglobulins.
The data strongly imply that the processing inhibitors have, in some way, 
rendered some of the immunoglobulin molecules susceptible to further modification
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by allowing the attachment of sialic acid residues to its carbohydrate chains. 
Whether this is a result of a de novo activation of the sialic acid transferase, or due 
to the structural modification of the N-linked oligosaccharide moiety that gives rise 
to substrate configuration for the enzyme's action, is a subject for further study.
3.3.2. Concanavalin A Affinity Chromatography.
Concanavalin A (Con A) is a lectin that binds preferentially to the core 
carbohydrate structure (see figure 3) of N-linked oligosaccharides. Many studies 
have shown that the affinity of the lectin binding interaction is dependent upon the 
structures of carbohydrate molecules. For example, Con A binds strongly to the 
biantennary complex-type glycopeptides possessing two peripheral NeuAc-Gal- 
GlcNAc units but has no affinity to the triantennary complex-type with similar 
sugar constituents (Krusius et al., 1976). The presence of a "bisecting" GlcNAc 
group linked 1-4 to the p-mannose residue of the trimannosyl core has also been 
shown to markedly weaken the N-linked carbohydrate moiety interaction with Con 
A (Narasimhan er a/., 1986).
In this study, two distinctive approaches were adopted in investigating the 
affinity interaction of the structures of N-linked oligosaccharides, synthesized in the 
presence of processing inhibitors, with Con A. Binding studies were performed on 
either, cleaved carbohydrate moieties from immunoprecipitated IgG2b molecules 
derived from treatment with endo H (or Glycopeptidase F in case of control 
samples) or, glycopeptides that are obtained from pronase treated samples. The 
method for the Con A affinity chromatography is described in section 2.6.5, and 
results of the experiments are illustrated in figure 30. For convenience, 
oligosaccharides or glycopeptides that are eluted by Con A buffer or lOmM methyl- 
a-D-glucopyranoside may be interpreted as having no or low affinity with Con A, 
and those eluted by lOOmM methyl-a-mannopyranoside or remained bound to Con
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Figure 30. Concanavalin A-sepharose chromatography of oligosaccharides/ 
glycopeptides of IgG2b secreted in the presence of processing inhibitors.
Panel a, Oligosaccharides derived from Endo H treatment (or Glycopeptidase F, in 
case of control) of IgG2b immunoprecipitates were analysed by Con A affinity 
chromatography. The Con A-sepharose beads column (200pl bed volume) was 
eluted with Con A buffer, lOmM methyl-a-D-glucopyranoside and lOOmM methyl- 
a-D-mannopyranoside, respectively. Eluents as well as the Con A-sepharose beads 
were then counted and the results are expressed in percentage of total radioactivity. 
Panel b, A similar Con A affinity chromatography was performed on Pronase- 
treated IgG2b immunoprecipitates.
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A-sepharose beads may be considered as having high affinity to the lectins 
(Reitman et ah, 1982).
The elution profile of control and processing inhibitor-treated samples 
from both oligosaccharides and glycopeptides are significantly distinct. Elution of 
control oligosaccharides obtained from digestion of immunoprecipitates with 
glycopeptidase F demonstrate approximately equal ratio of carbohydrate moieties 
with low and high affinity for Con A. In the presence of processing inhibitors, 
however, a greater fraction of oligosaccharides with high affinity for Con A is 
formed (approximate ratio of 4:1). This elution pattern is also observed in case of 
glycopeptides derived from pronase-treated immunoprecipitates. Immunoglobulins 
that are synthesized in the presence of oligosaccharide processing inhibitors, 
therefore, generally possess carbohydrate moieties with higher affinity to Con A. In 
addition, the different percentages of radioactivity that were detected from the 
various elutions also suggest the presence of structural heterogeneity of the 
carbohydrate moieties of immunoglobulins synthesized in the presence of 
oligosaccharide processing inhibitors, although this is not clearly observed from 
SDS-polyacrylamide gel resolution.
3.3.3. Elisa Titration of Rat hybridoma IgG2b»
The protocol for treatment of IIA 1.4 cells with tunicamycin and the 
processing inhibitors is described in section 2.8.1. Prior to assays for secondary 
functions, control and drug-treated samples were screened by Elisa. Figure 31 
demonstrates a typical example of the Elisa titration of IgG2bffom IIA 1.4 cells. 
The assay demonstrates that total inhibition of N-glycosylation or interference with 
the processing of the N-linked oligosaccharide chains of immunoglobulins have no 
effect on the antigen binding property of the immune molecules; an observation 
which parallels the previously reported data of Nose and Wigzell (1983). In 
absence of an accurate quantitative analysis for concentrations of IgG2 b secreted hy
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Figure 31. Elisa titration of rat hybridoma IgG2b-
Before subjecting to functional assays of immunoglobulins, culture supernatants 
from control and drug-treated samples were screened by Elisa. Microtitre plates 
were coated with 10^ Inaba vibrios per well and blocked with 0.5% (W/V) gelatin 
before adding the IIA 1.4 cell culture supernatants. Plates were incubated at room 
temperature for two hours and washed with PBS. lOOgl of HRP-RArlg solution 
was subsequently added to each well and plates were left for further incubation for 
another hour. Plates were washed again and then added with substrate solution until 
formation of colour was observed. Reaction was terminated by addition of H2 SO4  
to each well and colour was measured at 492nm in a Titretek Multiskan 
Spectrophotometer. Samples were analysed in duplicate.
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cells that are untreated and those that are exposed to tunicamycin or any of the 
processing inhibitors, and basing on the above observation that the oligosaccharide 
moieties of immunoglobulins have no roles in antigen binding, this procedure was 
also adopted to provide a general guide to the difference in concentrations of the 
secreted immunoglobulins. Throughout the course of this study, relatively similar 
results were achieved from culture supernatants that were generated and screened 
by the described methods.
The data are also supported by results that were obtained from the pulse- 
chase procedures as discussed in sections 3.1.6 and 3.2.2. By using 
immunoprecipitation, it was demonstrated that the rate of synthesis and secretion of 
untreated IgG2b similar to the kinetics of export from those cells that were 
exposed to the respective processing inhibitors (figure 21). Treatment of I1A1.4 
cells with tunicamycin, however, results in a slightly decreased secretion of 
immunoglobulins (figure 12). This effect is most likely due to the minor 
cytotoxicity of the glycosylation inhibitor on the cells rather than a direct inhibition 
on the rate of immunoglobulin export.
3.3.4. Effects of N-linked Oligosaccharide Processing Inhibition of IgG2b on
Ability to Fix Complement
In light of the finding that non-N-glycosylated IgGs are less effective in 
triggering the complement cascade (Koide et al., 1977; Winkelhake et al., 1980; 
Nose and Wigzell, 1983), it would be interesting to determine the effects of 
inhibition of N-linked oligosaccharide processing of immunoglobulins upon 
fixation of complement. After screening by Elisa (section 2.8.2), culture 
supernatants that are obtained from I1A1.4 cells that are untreated and those that 
have been exposed to tunicamycin or processing inhibitors (section 2 .8 .1), are 
thus, subjected to assay of complement fixation (for methods, see section 2.8.4).
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Figure 32 demonstrates a representative result that was obtained from the 
complement fixation assay of immunoglobulins from control, tunicamycin- and 
processing inhibitor-treated I1A1.4 cell culture supernatants. Assays were 
performed in duplicate. Results are expressed in terms of percentage complement 
fixation relative to control, i.e., complete lysis solution (section 2.8.4). The data 
demonstrate that non-N-glycosylated IgG2b *s e^ss effective in fixing complement 
than control antibody. This is explained by studies which have shown that in the 
absence of carbohydrate moieties, immunoglobulins bind less effectively with the 
C lq subcomponent of the complement cascade (Leatherbarrow et al., 1985). 
However, since the kinetic data suggest that in the presence of tunicamycin, IgG2b 
is secreted at a slightly reduced rate (figure 1 2 ), it is not possible, in this case, to 
conclude precisely whether the difference in complement fixation exhibited by the 
control and tunicamycin-treated culture supernatants is a consequence of structural 
modification of the antibody or simply an effect of a less concentrated antibody 
solution.
On the other hand, immunoglobulins possessing high mannose N-linked 
oligosaccharide structures that are secreted in the presence of the four distinct 
processing inhibitors, i.e., CSP, dNM, dMM and SW, demonstrate apparently 
potentiated capability in activating the complement cascade as compared to the 
untreated control molecules. Since the kinetic data from pulse-chase experiments 
(figure 21) and the Elisa titration curves of the samples that are used in this assay 
(figure 31) indicate no significant difference in concentrations between the 
processing inhibitor-treated and control culture supernatants, it is therefore 
reasonable to conclude that the potentiated effect in triggering the complement 
cascade demonstrated by the processing inhibitor-treated samples is really a result 
of the modified carbohydrate structures of IgG2b-
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Figure 32. Effects of N-linked oligosaccharide processing inhibition of IgG2b 011 
the fixation of complement
Complement fixation assay was performed according to the method described in 
section 2.8.4. Tubes consisting of different concentrations of I1A1.4 cell culture 
supernatants, 1 x 1 0 7 attenuated Inaba vibrios and guinea pig complement solution 
were incubated at 4°C overnight A panel of control tubes (in absence of antibody, 
antigen and complement, respectively) and tubes solely consisting of complement 
solution (i.e., "complete lysis tube") were also prepared. On the next day, 
haemolysin-sensitized sheep erythrocytes were added to each tube. Tubes were 
immediately incubated at 37°C until a complete lysis of the sheep erythrocytes was 
obtained from the "complete lysis tube". Tubes were simultaneously centrifuged at 
4°C to pellet debris and unbroken cells. Supernatants were then measured for 
absorbance readings at 492nm. Samples were analysed in duplicate. Results are 
expressed in percentage complement fixation relative to "complete lysis" control 
readings (section 2.8.4).
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This finding provides clues to the optimal structures involved in the 
binding interaction between antibodies and Clq protein. Currently, it is known that 
the IgM is generally more efficient in fixing complement than IgG (Roitt et al., 
1985). The Clq binding region on the immunoglobulin M has also been localized to 
the Qi4 domains (Hurst et al., 1971 and 1975; Bubb and Conradie, 1976), which, 
under normal circumstances, individually possess one N-linked oligosaccharide 
moiety (see figure 5). Structural analysis of the carbohydrate moieties of the r e ­
linked oligosaccharide chains at the Cji4 domains demonstrates that both possess 
high mannose configuration (Shimizu et al., 1971; Hickman et al., 1972). Taken 
together, these data and the data of figure 32 strongly suggest that the high mannose 
N-linked oligosaccharide structures of immunoglobulins (as reflected by their 
susceptibility to endo H digestion) are one of the critical factors that contribute to an 
effective interaction with the Clq protein.
The earlier data from figure 29 (neuraminidase analysis of carbohydrate 
structures), however, suggest that the structures of carbohydrate residues that are 
generated in the presence of each oligosaccharide processing inhibitor, although 
demonstrating susceptibility to endo H digestion (panel b of figures 22-25), are still 
partly processed to the complex form. This is evident from their susceptibility to 
neuraminidase digestion. The complex-type N-linked oligosaccharide chains from 
normal IgG2 5  from HA 1.4 cells do not possess sialic acid residues as demonstrated 
by their resistance to the enzyme treatment. Thus, the potentiated effect in 
complement fixation that are observed in cases of processing inhibitor-treated 
immunoglobulins (figure 32) could have also arisen as a result of the differences in 
terminal carbohydrate structures. This is, however, refuted by reports (Koide et 
al., 1977), which demonstrate that in case of N-linked oligosaccharides of IgGs 
containing terminal galactose and sialic acid residues, enzymatic removal of the 
sugar moieties by neuraminidase and p-galactosidase does not result in any changes 
to the complement fixation activity of the immunoglobulin.
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The IIA 1.4 cell line that is used in this study is, unfortunately, not the
optimum model system with which to perform complement fixation assay*;
Antibodies produced by this rat hybridoma cells are directed against the LPS-
coating of the Inaba strain of Vibrio cholerae (Ghosh and Campbell, 1986). The
Clq subcomponent of the complement cascade is well known for its high non-
immunological reactivity with a variety of antigens, e.g., acidic
mucopolysaccharide, heparin, protamine, DNA and envelope glycoprotein of
certain oncoviruses (McConnel et al., 1981). In this case, the Clq molecule has
also been discovered to react with lipopolysaccharide (data not shown).
Consequently, it is not possible to perform direct binding assay involving
♦
radiolabeled Clq proteins.
3.3.5. Effects of N-Linked Oligosaccharide Processing Inhibitors on Assay of
Complement Fixation.
One of the arguments that may be advanced against the above complement 
fixation data concerns the effects the processing inhibitors themselves may have on 
the assay. Processing inhibitor-treated culture supernatants that were used in *the 
complement fixation assay, all contain the drugs to which the cells have been 
exposed, and which may, therefore, have contributed to the observed potentiation 
effects. To test this notion, a complement fixation assay was performed on control 
culture supernatants that have been supplemented with the various processing 
inhibitors at their characteristic concentrations.
Figure 33 shows the complement fixation curves from assays of control 
and processing inhibitor-supplemented IIA 1.4 culture supernatants. As clearly 
illustrated, there is no significant difference that could be detected between the 
control and samples that have been added with tunicamycin or the processing
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Figure 33. Effects of tunicamycin and N-linked oligosaccharide processing 
inhibitors on complement fixation.
To determine the effects of tunicamycin and N-linked oligosaccharide processing 
inhibitors on complement fixation, assay was performed on control samples 
supplemented with the various inhibitors at their respective concentrations. Samples 
were analysed in duplicate.
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inhibitors. The data unequivocally illustrate that the processing inhibitors have no 
direct effect on the complement fixation activity and therefore substantiate the 
hypothesis that high mannose structures of the IgG2b molecules are more effective 
in triggering the complement cascade than the naturally processed complex-type 
configurations.
3.3.6. Effects of Monosaccharides on Assay of Complement Fixation.
In the report by Koide et al. (1977), apart from demonstrating that non- 
N-glycosylated IgG are less effective in activating the complement cascade, it was 
also shown that the presence of free sugars, i.e., N-acetylglucosamine, N- 
acetylgalactosamine, mannose and galactose, at lOOmM concentrations, results in a 
substantial degree of inhibition of the complement fixation activity. The data 
provide considerable support to the hypothesis that high mannose oligosaccharide 
structure provides certain advantages in fixing complement than the complex-type 
glycan. Free sugar residues may have acted as competitors in the binding of the first 
component of the complement cascade.
To verify this observation, complement fixation assays were performed 
on control untreated samples in the absence and presence of 5mM mannose, N- 
acetylglucosamine and galactose. If the free monosaccharides do act as competitive 
inhibitors to the Clq binding interaction, the 5mM concentration of sugars that was 
used should be sufficient to cause a shift in the complement fixation profile, relative 
to the control. Additions of higher concentrations of the sugars may indirectly 
interfere with the method of complement fixation assay instead.
Figure 34 demonstrates the complement fixation curves achieved from 
assays of IIA 1.4 cell culture supernatants in the absence and presence of 5mM 
mannose, N-acetylglucosamine and galactose. The data clearly demonstrate that
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Figure 34. Effects of monosaccharides on complement fixation.
To determine the effects of sugars on complement fixation, assay was performed on 
control samples supplemented with the various monosaccharides at 5mM 
concentration. Samples were analysed in duplicate.
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none of the sugars that were added have any effect bn the complement fixation 
activity by rat hybridoma IgGjb- This finding contradicts the earlier published 
report (Koide et al., 1977) which suggested that free sugar residues may act as 
competitive inhibitors in the Clq binding activity, although the concentration of 
monosaccharides that was used in the earlier study is twenty times higher than those 
that are described in this thesis.
3.3.7. Effects of N-Linked Oligosaccharide Processing Inhibition on
Agglutinating Activity of IgG^.
While complete carbohydrate digestion of the IgG molecules causes 
considerable impairment on the antibody's function to fix complement, no effects 
was observed on its haemagglutination activity (Koide et al,y 1977). By subjecting 
the untreated I1A1.4 cell culture supernatants and those derived from cells that have 
been exposed to tunicamycin and the processing inhibitors to haemagglutination 
assay (for methods, see section 2 .8 .6 ), a similar result was also obtained.
Haemagglutination assay was performed by mixing the various culture 
supernatants at different dilutions with lipopolysaccharide-coated sheep 
erythrocytes (section 2.8.6). Figure 35 demonstrates that the end-point 
agglutinating titre is the same in all cases. Agglutination are observed in wells 
containing culture supernatants ^ t 1:1 and 1:2 dilutions but not at the 1:4 antibody 
dilution.
The above structural analysis of carbohydrate moieties of IgG2b isolated 
from cells treated with N-linked oligosaccharide processing of inhibitors has led to 
an intriguing observation. The carbohydrate moieties of normal IgG2 b molecules do 
not possess any terminally linked sialic acid residues as shown by their resistance to 
neuraminidase digestion. However, when the cells were exposed to the 
oligosaccharide processing inhibitors (individually or simultaneously), a fraction of
126
Figure 35. Effects of N-linked oligosaccharide processing inhibition on 
agglutinating activity of IgG2b*
Haemagglutination assay was performed as in the method described in section
2 .8 .6 , i.e., by mixing the various culture supernatants with lipopolysaccharide- 
coated sheep erythrocytes. Samples were analysed in duplicate.
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CSP - culture supernatant of castanospermine-treated II A l.4 cells
dMM - culture supernatant of 1-deoxymannojirimycin-treated II A1.4 cells
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the secreted immunoglobulins demonstrate susceptibility to the enzyme. In addition, 
the study has also demonstrated the presence of structural heterogeneity of the N- 
linked oligosaccharide moieties synthesized in the presence of the processing 
inhibitors when the oligosaccharide were analysed on their binding interaction with 
Con A.
Investigation of the effects of N-linked oligosaccharide processing 
inhibition on the functional activities of immunoglobulins have provided  a few 
interesting observations. Non-N-glycosylated IgG2b was firstly demonstrated to be 
less effective in fixing complement. Immunoglobulins with high mannose 
structures that were synthesized in the presence of processing inhibitors, on the 
other hand, demonstrate potentiated capabilities in activating the complement 
cascade. The structural modification of the carbohydrate residues of IgG2 b by the 
processing inhibitors have, however, no effect on the antigen binding and 
haemagglutination activities of the immunoglobulins.
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SECTION 3.4. 
GENERAL CONCLUSIONS.
1 2 9
The question that often arises from studies employing tunicamycin as the 
biological tool to assess the role of N-linked oligosaccharide moieties in controlling 
transport of glycoproteins is whether the drug may directly interfere with the 
biological activities of the cell. This is of prime importance since direct interference 
of the antibiotic may totally dissolve the usefulness of this tool and discredits the 
data obtained from its experiments. This thesis has described a study characterizing 
three different structural analogues of tunicamycin. It has shown that the integrity of 
every structural component of tunicamycin is highly essential for its ability to inhibit 
N-glycosylation as well as the intracellular transport of IgM molecules. It was 
further demonstrated that the modified tunicamycins have no pronounced effects on 
the synthesis of cellular macromolecules. From these observations, it was deduced 
that the tunicamycin-associated cytotoxicity and the selective inhibition of 
glycoprotein export are secondary responses of the cells resulting from the 
inhibitor's primary actions. The structural analogues of tunicamycin were then, also 
shown not to interfere with the N-acetylglucosaminyl transferase I and II residing in 
the golgi apparatus.
The role of N-linked oligosaccharide processing in the control of transport 
of rat hybridoma immunoglobulins were also investigated. Inhibition of the 
processing of N-linked oligosaccharides of rat hybridoma IgG2b anc* IgM has been 
shown to have no effect on the kinetics of immunoglobulin export. Taken together, 
the data provide substantial support for the view that carbohydrate moieties have no 
general role in regulating the transport of glycoproteins. This is compatible with the 
recent emerging hypothesis that the intracellular transport of glycoproteins does not 
require any form of promoting mechanism. Glycoproteins may be channeled quite 
efficiently via the rapidly-occuring constitutive bulk flow process. Involvement of 
the regulatory ligand-receptor mechanism only applies for proteins to be retained in 
specific intracellular compartments. In cases where inhibition of N-glycosylation or
1 3 0
carbohydrate processing leads to markedly retarded protein export, other factors 
may have been the cause. Absence of carbohydrate moieties or interference with 
their intracellular processing may severely alter the physicochemical property of 
proteins, and thus, prevent their transport. Alternatively, the structural 
modifications may also result in exposure of specific sites on the molecules which 
may then interact with intracellular retention proteins.
The structures of carbohydrate moieties of immunoglobulins derived from 
cells exposed to the N-linked oligosaccharide processing inhibitors were also 
studied. Inhibition of N-linked oligosaccharide processing appears to be a more 
complex situation than initially expected. Immunoglobulins synthesized in the 
presence of CSP, dNM or mixtures containing either of these glucosidase inhibitors 
demonstrate higher Mr as resolved by SDS-PAGE. There was considerable 
structural variation amongst the carbohydrate structures of immunoglobulins 
synthesized in the presence of all of the oligosaccharide processing inhibitors. In 
case of the IgG2 b fr°m I1A1.4 cells, inhibition of N-linked oligosaccharide 
processing is further associated with the transfer of sialic acid residues to the 
carbohydrate chains (N-linked carbohydrate moieties of normal IgG2b fr°m HA 1.4 
cells do not possess any sialic acid residues).
Finally, the effects of inhibition of N-glycosylation or N-linked 
oligosaccharide processing on the functional activities of IgG2b of rat hybridoma 
was investigated. The data demonstrate that non-N-glycosylated immunoglobulins 
are less effective in activating the complement cascade. On the other hand, 
immunoglobulins synthesized in the presence of the oligosaccharide processing 
inhibitors demonstrate potentiated capability in fixing complement. Neither the 
inhibition of N-glycosylation nor the carbohydrate processing has any effect on the 
antigen binding and haemagglutination activities of the immunoglobulins.
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